



**Vaccines and Global Health: The Week in Review**  
**6 March 2021 :: Issue 597**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. **This blog allows full text searching of over 21,000 entries.***

*Comments and suggestions should be directed to*  
David R. Curry, MS  
Editor and  
Executive Director  
Center for Vaccine Ethics & Policy  
[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

**Request email delivery of the pdf:** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

**Support this knowledge-sharing service:** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

**Contents** *[click on link below to move to associated content]*

- A. [Milestones :: Perspectives :: Featured Journal Content](#)
- B. [Emergencies](#)
- C. [WHO; CDC \[U.S., Africa, China\]](#)
- D. [Announcements](#)
- E. [Journal Watch](#)
- F. [Media Watch](#)

## ***Milestones :: Perspectives :: Research***

### ***Editor's Note:***

As is obvious to all, the sheer volume of strategic announcements, regulatory actions, country program decisions, commentary, and, indeed, misinformation around COVID response continues at extraordinary levels. Our weekly digest strives to present a coherent and comprehensive snapshot, but cannot be exhaustive. If you recognize a missed strategic development, a new source of rigorous analysis, or an insight/commentary that would benefit our common understanding, please advise me...we will review suggestions and consider inclusion in a subsequent edition:

[david.r.curry@ge2p2global.org](mailto:david.r.curry@ge2p2global.org)

.....  
.....

### **Rotavirus vaccines made available for use in humanitarian crises**

*Health partners welcome landmark pricing agreement through Humanitarian Mechanism, urging more manufacturers to follow suit*

4 March 2021 News release Geneva/London/New York

Médecins Sans Frontières (MSF), Save the Children, UNICEF and the World Health Organization (WHO) welcome the opportunity to make rotavirus vaccine available to more children living in humanitarian crises **thanks to a landmark pricing agreement with the manufacturer, GSK.**

Children living in refugee camps, displaced communities or in other emergency situations now have a better chance of being protected against severe diarrhoeal disease with these lower price rotavirus vaccines. Diarrhoea is one of the leading causes of death among children under five.

**The agreement makes use of the multi-partner Humanitarian Mechanism, launched in 2017. Rotavirus vaccine is the second vaccine to be accessed through the scheme**, which depends on manufacturers making their vaccines available at their lowest price for use in emergencies - across countries of all income levels. The first to be made available was the pneumococcal vaccine.

"We welcome this engagement from manufacturers and hope it will be a step towards making more vaccines available in the future at affordable prices," said Dr Kate O'Brien, Director of Immunization, Vaccines and Biologicals at WHO. "It is unacceptable that some of the most at-risk children are not vaccinated against devastating diseases like rotavirus because of lack of availability or high costs."... The Humanitarian Mechanism facilitates access to vaccines for humanitarian organizations working in countries affected by emergencies, where access and prices have otherwise been a bottleneck...

**Since 2017, nearly one million doses of pneumococcal vaccine have been approved for use by civil society organizations through the Mechanism in 12 countries:** Algeria, Central African Republic, Chad, Democratic Republic of the Congo, Ethiopia, Greece, Kenya, Lebanon, Niger, Nigeria, South Sudan and Syria. The pneumococcal vaccine protects against childhood pneumonia, also a leading cause of childhood deaths during emergencies.

**Once secured through the Mechanism, the vaccines are offered to humanitarian organizations working in camps and other emergency settings, who can make applications to access the vaccine at these lower prices.**

"The Humanitarian Mechanism has already expanded the number of children who can receive lifesaving vaccines, but to reach its full potential and save more lives, MSF calls on manufacturers to commit additional vaccines and to allow governments hosting children in humanitarian emergencies to access the vaccines too," said Miriam Alia, Vaccination and Outbreak Response Referent at MSF. "Children everywhere, no matter where they live, should have access to lifesaving vaccinations."...

.....  
.....

## **COVID Vaccines – UN Security Council; UNESCO**

### **Security Council Calls for Increased Global Cooperation to Facilitate COVID-19 Vaccine Access in Conflict Areas, Unanimously Adopting Resolution 2565 (2021)**

26 February 2021

SC/14454

The Security Council today announced the adoption of a resolution calling for strengthened international cooperation to facilitate equitable and affordable access to COVID-19 vaccines in armed conflict and post-conflict situations, and during complex humanitarian emergencies.

Acting through its special silence procedure enacted during the pandemic, the Council unanimously adopted [resolution 2565 \(2021\)](#), **recognizing the role of extensive immunization against COVID-19 as a global public good for health. It stressed the need to develop international partnerships, particularly to scale-up manufacturing and distribution capabilities, in recognition of differing national contexts.**

By other terms, **it reiterated its demand for a general and immediate cessation of hostilities in all situations on its agenda, demanding as well that all parties to armed conflicts engage immediately in a durable, extensive, and sustained humanitarian pause to facilitate the equitable, safe and unhindered delivery and distribution of COVID-19 vaccinations in areas of armed conflict.**

Reaffirming that these calls do not apply to military operations against Islamic State in Iraq and the Levant (ISIL/Da'esh), Al-Qaida and Al-Nusra Front, or their associates, the Council demanded that all parties to armed conflicts fully comply with their obligations under international law.

**Further, the Council requested the Secretary-General to provide a full assessment of the impediments to vaccine accessibility and the COVID-19 response, including vaccination programmes, in situations of armed conflict and complex humanitarian emergencies — and as necessary, make recommendations to the Council.** It expressed its intention to review situations brought to its attention by the Secretary-General where hostilities and armed group activities are impeding COVID-19 vaccination and to consider what further measures may be necessary to ensure such impediments are removed, and hostilities paused to enable vaccination.

**It emphasized the urgent need for "solidarity, equity and efficacy",** inviting donation of vaccine doses from developed economies and all those in a position to do so to low- and middle-income countries and other countries in need, particularly through the COVAX Facility — a global mechanism for pooled procurement and equitable distribution of COVID-19 vaccines.

*[Security Council resolutions are currently adopted through a written procedure vote under temporary, extraordinary and provisional measures implemented in response to the COVID-19 pandemic, as set out in a letter (document [S/2020/253](#)) by its President for March 2020 (China).]*

.....

### **UNESCO calls for COVID-19 vaccines to be considered a global public good**

24/02/2021

UNESCO's International Bioethics Committee (IBC) and the World Commission on the Ethics of Scientific Knowledge and Technology (COMEST) have called for a change of course in current COVID-19 vaccination strategies, urging that vaccines be treated as a global public good to ensure they are made equitably available in all countries, and not only to those who bid the highest for these vaccines. Both committees have a long track record in providing ethical guidance on sensitive issues\*.

The statement was presented during an online event on 24 February, which gathered UNESCO's ethics bodies together with Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, and Professor Jeffrey Sachs from Columbia University.

The IBC-COMEST Statement stresses three key messages:

**Firstly, pharmaceutical industries have a responsibility to share the intellectual property acquired with government support to enable manufacturers in all countries to provide access to vaccines for all**, which should be considered a global public good. The IBC and COMEST also stress the responsibility of the pharmaceutical industry to invest in factories capable of producing vaccines of the highest possible efficacy and facilitating rapid distribution where needed.

**Secondly, the IBC and COMEST say that the vaccine's benefit to the greatest number of people cannot be considered the sole ethical criterion. Equality, equity, protection from vulnerability, reciprocity and the best interests of children must also be taken into account.** Furthermore, decisions on fair distribution and prioritization should be based on the advice of a multidisciplinary group of experts in bioethics, law, economics, and sociology, together with scientists.

**Thirdly, the IBC and COMEST consider that vaccination strategies should be based on a non-compulsory, non-punitive model, grounded in information and education, including dialogue with people who may be hesitant about vaccination or hostile to it. Refusing to be vaccinated should not affect the individual's fundamental rights, specifically his or her right to access healthcare or employment.**

Other issues the statement covers include: international cooperation across all different sectors working on COVID-19 to share the benefits of research; the sustainability issues that favour the emergence of zoonotic diseases; trust in science and healthcare authorities; the indispensable need for dialogue between science, ethics, politics and civil society.

.....

.....

## [World Bank Bond Expands Support to COVID-19 Resilience Through the United Nations Children's Fund \(UNICEF\)](#)

Washington, DC, March 4, 2021—The World Bank (International Bank for Reconstruction and Development or IBRD) has issued a US\$100 million 5-year bond which both supports IBRD's ongoing sustainable development and COVID-19 activities and adds a new feature to support similar efforts by the United Nations Children's Fund (UNICEF). As countries confront the economic challenges of the pandemic, which has affected millions of children worldwide, the issuance will channel an amount equivalent to half of the total proceeds, US\$50 million, to UNICEF. This frontloading of financing to UNICEF will support its pandemic response programs for children around the world over the 5-year period.

"This World Bank bond serves as an example of how the private sector can share financial risks to achieve positive development impact," said David Malpass, World Bank Group President. He added, **"We are grateful to our investors for joining this effort and demonstrating how investors can participate in the global response to COVID-19, through this unique opportunity to scale up resources available to UNICEF to expand its programs.** The bond also spotlights impact investor support for World Bank Sustainable Development Bonds and the potential for finding new ways to collaborate for impact."

**"The COVID-19 pandemic has exacerbated deep inequalities within and across countries worldwide," said Henrietta Fore, UNICEF Executive Director. "Keeping children at the heart of recovery efforts and focusing on innovative partnerships will enable us to reimagine children's futures and secure more equitable societies."**

"Making real headway in alleviating social challenges requires new ways of doing things. We're excited to innovate in the financial space and our institutional and private clients have shown overwhelming support for investments that can further their social missions," said Jim O'Donnell, Head of Citi Global Wealth.

.....  
.....

## [Coalition of International NGOs Call for Equitable Access for Vaccines and Treatment during COVID-19 Pandemic](#)

Mar 4, 2021

...On February 11, 2021, the World Federation of Public Health Associations hosted a historic meeting to initiate a coalition amongst leaders from international NGOs who share a common interest in equitable access for vaccines and treatment during COVID-19.

The organizations agreed to work together to build and sustain equity in global public health through increased advocacy for social protection and social development in vulnerable communities. Moreover, **leaders expressed the need for an environmentally conscious and safe way to develop, distribute, and deliver vaccines, as this will also help reduce inequity following the pandemic by ensuring we do not exacerbate adverse climate effects.** The Coalition is committed to engaging with other organizations, governments, and key stakeholders to achieve a coordinated response to the pandemic. The organizations will dedicate themselves to continue compiling resources, sharing evidence-based best practices, and using their collective voice to advocate

for those who are disproportionately harmed by the pandemic, including chronically ill patients, individuals lacking access to health care services and medication, and marginalized communities.

Therefore, together we call on the World Health Assembly, the G20, every government, and all organizations that engage in public health, social policy, and advocacy to make the ethical choice now for the health and the economic well-being of all populations globally, especially the most vulnerable — leaving no one behind.

**We call on all of these actors to work together to:**

- :: Guarantee more and equitable access to vaccines
- :: Increase the health care, public health, and social protection workforce
- :: Challenge uncoordinated social, economic, and health system dynamics to maximize vaccine production, distribution, and uptake
- :: Address the national and international spending priorities during the pandemic
- :: Guarantee an environmentally and economically sustainable and equitable production and distribution of the vaccines
- :: Engage all groups in society, including youth and young professionals, key stakeholders, and health professionals in the decision-making process and implementation
- :: Engage with civil societies, patient organizations, and the broader public across diverse communities to address communication, including risk communication, tackling misinformation and combatting hesitancy, on every level.

Overall, we believe that this growing Coalition has immense potential to strengthen our individual and collective responses to inequity, which like the virus itself, works beyond national borders both during the pandemic and in the years of recovery to follow. We are keen to begin this important work, and we look forward to contributing to and sharing our joint initiatives across our extensive networks...

*Signed by:*

FDI World Dental Federation  
Healthcare Without Harm  
International Alliance of Patients' Organizations  
International Council of Nurses  
International Federation on Ageing  
International Federation of Environmental Health  
International Federation of Medical Students' Associations  
International Federation of Social Workers  
International Hospital Federation  
International Pharmaceutical Federation  
International Pharmaceutical Students' Federation  
International Physicians for the Prevention of Nuclear War  
International Veterinary Students' Association  
The European Forum for Primary Care  
The Global Ageing Network  
Union for International Cancer Control  
WHO Collaborating Centre on Family Medicine and Primary Health Care - Ghent University  
World Association for Disaster and Emergency Medicine  
World Federation of Public Health Associations  
World Heart Federation

World Organization of Family Doctors  
World Patients Alliance  
World Physiotherapy

.....  
.....

## **COVAX: Vaccine Supply/Allocation**

### **The COVAX Facility – FIRST ROUND OF ALLOCATION: ASTRA ZENECA/OXFORD VACCINE (manufactured by AstraZeneca & licensed and manufactured by Serum Institute of India)**

*Feb-May 2021 - last updated 2 March 2021*

#### ***Introduction***

Following from the publication of an interim distribution forecast, and based on current knowledge of supply availability, this first round of allocations provides information on provision of doses of the AstraZeneca(AZ)/Oxford vaccine to COVAX Facility participants, through May 2021.

This first round allocation outlines delivery of 237 million\* doses of the AZ/Oxford vaccine – manufactured by AstraZeneca (AZ) & licensed and manufactured by Serum Institute of India (SII/AZ) – to 142 Facility participants.

*[\*This total does NOT include 5% of supply set aside for Humanitarian & Contingencies Buffer, not yet approved by Gavi Board]*

This list will be updated by the end of the week to provide indicative timelines for the supply of these doses, split into Feb-March and April-May. These timelines are dependent on a variety of factors including national regulatory requirements, availability of supply, and fulfilment of other criteria such as validated national deployment and vaccination plans (NDVPs) from AMC participants, indemnification & liability agreements, and export and import authorisations.

Participants not listed have either exercised their rights to opt-out of this vaccine, wish to transfer allocated doses to AMC participants, are AMC-eligible but have not joined the AMC, have voluntarily delayed receipt of doses and communicated this intent ahead of allocation, or have not met financial requirements.

In addition to this first round of allocations, an exceptional distribution of 1.2 million doses of the Pfizer-BioNTech vaccine, anticipated for delivery in Q1 2021, was announced in early February. These doses are reflected in the table below, to provide a global overview of allocations to-date but are not part of this round of allocation.

Further allocation rounds for vaccines in the COVAX portfolio will be announced in due course.

#### ***Overview of the process***

This first round of allocation took place as per the Fair allocation mechanism for COVID-19 vaccines through the COVAX Facility, which was developed by WHO in consultation with its Member States. This allocation framework for fair and equitable access to COVID-19 health products sets forth the criteria and approach to allocation of vaccines through the COVAX Facility.



The operationalization of the Framework, in accordance with the principles and provisions set forth in the document above, is performed by the Joint Allocation Taskforce (JAT), composed of staff from Gavi, the Vaccine Alliance and WHO, and the [Independent Allocation Vaccine Group \(IAVG\)](#). The main purpose of the IAVG is to make validation assessments of proposals for Vaccine Allocation Decisions ("VAD proposals"), which outline the volumes

of Vaccines that should be allocated to each country/economy participating under COVAX within a given time frame. The IAVG will consider VAD proposals prepared and submitted by the JAT. The IAVG met twice over 22 and 23 February 2021 to discuss this first round of allocation. All 12 IAVG members were present during both meetings, and therefore full quorum was achieved. The deliberations resulted in consensus and no divergent views were recorded on the proposed allocation. As is normal procedure, the IAVG allocation report was then validated by the WHO Deputy Director-General, and the decision was communicated to the Office of the COVAX Facility, administered by Gavi.

***TABLE: Allocations by Facility participant***

*Note: Table will be updated later this week to provide further information on anticipated supply timelines, split into February-March and April-May 2021.*

*[138 countries listed at title link above including an allocation for "non-UN Member States" of 1,125,600 doses of AZ]*

.....

**[Independent Allocation of Vaccines Group \(IAVG\)](#)**

*[WHO webpage – accessed 6 Mar 2021]*

One of the principal objectives of COVAX is to promote the fair and equitable allocation of COVID-19 vaccines that are procured or distributed through COVAX (the "Vaccines") to countries and economies participating in COVAX. To achieve such objective, the mechanism through which Vaccines are allocated must be transparent and independent.

In this context, WHO, Gavi and CEPI (collectively, the "COVAX Partners") support the establishment by WHO of an Independent Allocation of Vaccines Group ("IAVG") pursuant to the WHO Regulations for Study and Scientific Groups, Collaborating Institutions and Other Mechanisms of Collaboration, and in accordance with these Terms of Reference. The IAVG is expected to play a pivotal role in the allocation of Vaccines under COVAX and to foster the independence of, and provide transparency into, the Vaccine-allocation decision-making under COVAX.

The main purpose of the IAVG is to make validation assessments of proposals for Vaccine Allocation Decisions ("VAD proposals"), which outline the volumes of Vaccines that should be allocated to each country/economy participating under COVAX within a given time frame. The IAVG will consider VAD proposals prepared and submitted by the Joint Allocation Taskforce ("JAT"), composed of WHO and Gavi staff.


The IAVG will have the following functions:

- :: To review the VAD proposals submitted by the JAT and to request clarifications from the JAT when necessary;
- :: To discuss with the JAT any adjustments to the VAD proposals considered necessary on the basis of IAVG's critical assessment;




- :: To make validation assessments of the VAD proposals, ensuring they are technically informed and based on the latest available data and evidence;
- :: For each VAD proposal that is validated by the IAVG (hereinafter a "VAD"), to document and justify the validation of such VAD, including any adjustments made to the original VAD proposal submitted to the IAVG by the JAT;
- :: To deliver the VADs to the WHO Deputy-Director General for further implementation by the JAT.

## The Allocation Mechanism for vaccines interacts directly with the COVAX facility



## The JAT and IAVG formulate a vaccine allocation decision, passed on to COVAX facility for implementation



.....

## **Independent Allocation of Vaccines Group (IAVG) Members – as of January 2021**

### ***Members***

Professor Anna Mia Ekström  
Dr Arlene King  
Christopher Maher  
Dr Narendra Kumar Arora  
Dr Bruce G. Gellin  
Dr Dafrossa Cyrily Lyimo  
Professor Tjandra Aditama  
Doctor Alejandro Cravioto  
Maria Guevara  
Dr Manica Balasegaram  
Dr Poh Lian Lim  
Dr Masahiko Hachiya

***Terms of Reference:*** <https://www.who.int/groups/iavg/terms-of-reference>

.....

### ***Documents and reports***

22 February 2021

## **Report of the Independent Allocation of Vaccines Group on the allocation of COVAX Facility secured vaccines: 22 February 2021**

### ***Overview***

This report covers the first Allocation of Astra Zeneca vaccines produced at the following two sites for which WHO issued an Emergency Use Listing on 15 February 2021:

:: Serum Institute of India Pvt Ltd - COVID-19 Vaccine (ChAdOx1-S [recombinant]) - COVISHIELD™ - "SII AZ"

:: AstraZeneca/SKBio - COVID-19 Vaccine (ChAdOx1-S [recombinant]) - "AZ" ...

.....

### ***Annexes***

## **Report of the Joint Allocation Taskforce (JAT) on the distribution of COVAX Facility secured vaccines**

### **COVAX FACILITY DISTRIBUTION of Astra Zeneca vaccines produced at two different sites: SK BIO in Republic of Korea and Serum Institute of India Pvt Ltd**

Date of report 19 February 2021

### ***Summary***

:: The current distribution round is enclosing allocation of Astra Zeneca vaccines produced by two different manufacturers at the following two sites for which WHO issued an Emergency Use Listing on 15 February 2021:

>> Serum Institute of India Pvt Ltd - COVID-19 Vaccine (ChAdOx1-S [recombinant]) – COVISHIELD™ - "SII AZ" ♣

>> AstraZeneca/SKBio - COVID-19 Vaccine (ChAdOx1-S [recombinant]) - "AZ"

**:: To date, 1,200,420 M doses of vaccine (Pfizer) have been allocated in a separate and distinct process (more details here) which was performed on 29 January 2021. These are referred to as “First Wave” doses.** This was due to specificities pertaining to the Pfizer/ BioNTech deal as well as learning objectives. These doses are not included in this allocation round, however coverage reached in the participants that received these early doses are reflected in the allocation. **To date no doses have been shipped to the 18 First Wave participants.**

:: Supply needs for a COVAX Buffer are also factored in this allocation – with 5% of total available supply set aside. Further information is available in the Supply section below.

**:: Considering the supply and demand characteristics, the overall number of doses to be distributed is 237,468,000 to 142 participants for the period January to May 2021 for AZ and SII AZ**

:: Given the supply available (and the 2-dose regime) and the population of all the participants in this round, **the average proportion of population covered in this round across countries is 5.52% (not weighted for population size)...**

.....  
.....

Statement 03/02/2021

**[Remarks by Henrietta Fore, UNICEF Executive Director at COVAX media briefing on first deliveries and first round of allocations](#)**

*As prepared for delivery*

NEW YORK, 2 March 2021 – “The last year has been a dark one for families all over the world, but the rapid development of COVID-19 vaccines provided a hopeful light at the end of the tunnel. At long last, the COVAX Facility begins to make good on its promise to make sure that light shines for all.

**“And we are off and running. Vaccine doses have arrived in West Africa and Asia, with many more countries to follow in the coming days and weeks. We’ve now seen Africa’s first vaccinations with COVAX doses in Ghana and Ivory Coast, in truly moving ceremonies in both countries yesterday.**

“But what took place Monday is more than a feel-good story that speaks to our collective best natures, it is a necessary first step that speaks to our collective best interests. The only way out of this pandemic is to ensure vaccination is available around the globe, and that people from less wealthy countries are not left behind in the race to be protected.

“At UNICEF, we are committed to making this happen. **Last week’s momentous arrivals are just the first batches of vaccines that UNICEF will ship through the COVAX Facility as part of this historic effort to deliver close to 2 billion doses of COVID-19 vaccines to around 190 countries and territories. To date, more than 1.1 million doses have been delivered, with more than twenty more countries expected to receive hundreds of thousands of doses this week.**

"I would like to thank SII for being the first to help deliver vaccines to AMC countries and for working around the clock to package and make vaccines available in record time, as well as to the Government of India for their immense support. We have a lot of work ahead of us.

"In terms of delivery, UNICEF is also working closely with airlines and other partners to find innovative solutions to help us deliver COVAX vaccines as quickly as possible. We've already seen tremendous partnership. I would like to thank freight forwarders and Emirates Airlines for helping UNICEF with shipments to Ghana and Ivory Coast in record turnaround time. **Only today we have 5 shipments including to DRC, Angola and Nigeria where we are delivering COVID19 vaccines consolidated with syringes and routine vaccines insuring children are also protected, among many other 20 countries receiving vaccines this week.**

**"We have also supported governments in developing national vaccination plans** and preparing for the arrival of vaccines. Along with our partners, we have mapped out existing cold chain equipment and storage capacity. And we have delivered and installed thousands of new fridges to keep vaccines at the right temperature in health facilities this past year. In Ghana, for example, we have delivered 2,500 fridges since May of last year. But much work still remains.

"With each of these steps, we move closer to the moment when we can start to return to normal for the billions of children and families affected around the world. And this is, obviously, our focus at UNICEF. Over the next couple of weeks, we will be talking a lot about how this pandemic has impacted the lives of children, starting later today when we will be issuing estimates of the number of children who have been unable to attend class in person for almost the entire past year...

"These are remarkable efforts, and the work we all – the private sector, UN and development agencies, governments, donors, and other partners – will doubtlessly continue to do more moving together, and will stand for generations to come as proof of what the world can do, when we do it together. It is history in the making. Thank you."

.....  
.....

### **Coronavirus [COVID-19] - WHO**

*Public Health Emergency of International Concern (PHEIC)*

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

### ***Weekly Epidemiological and Operational updates***

Last update: 23 January 2021

**Confirmed cases ::** 115 653 459 [week ago: 113 076 707] [two weeks ago: 110 384 747]

**Confirmed deaths ::** 2 571 823 [week ago: 2 512 272] [two weeks ago: 2 446 008]

**Countries, areas or territories with cases ::** 223













.....  
.....

### **WHO: Regulation and Prequalification**

**Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 24 Feb 2021**

For 16 vaccine candidates, the presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date  
**[click on the link above for full scale view]**

### Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process

	Manufacturer	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Anticipated decision date***
1.	 <b>Pfizer</b> <small>BIONTECH</small>	BNT162b2/COMIRNATY Tozinameran (INN)	EMA	Nucleoside modified mRNA	✓	✓	✓	Finalized	31/12/20
2.	 <b>AstraZeneca</b> <small>ZYNOVA</small>	AZD1222	Core – EMA Non-COVAX	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	Accepted core data of AZ – non-Covax Data for Covax expected in March 2021	Non-Covax Core data. Awaited	NA March – April 2021
3.	 <b>SK BIO</b> <small>AstraZeneca</small>	AZD1222	MFDS KOREA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021
4.	 <b>Serum Institute of India</b>	Covishield (ChAdOx1_nCoV-19)	DCGI	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021
5.	 <b>Sinopharm</b> / <b>WIBP</b> <sup>1</sup>	SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCoV)	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	In progress	Earliest March
6.	 <b>Sinovac</b>	SARS-CoV-2 Vaccine (Vero Cell), Inactivated	NMPA	Inactivated, produced in Vero cells	✓	✓	Additional still expected		Earliest March
7.	 <b>moderna</b>	mRNA-1273	EMA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	✓	✓	In progress (company to clear reviewers)	Earliest March
8.	 <b>Janssen</b> <small>Biotech Sciences</small>	Ad26.COV2.S	EMA	Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein	✓	✓	✓	Core data (US + NL sites) Use abridged procedure relying on EMA	In progress. In March 3 – 5 days after EMA
9.	 <b>THE GAMALEYA NATIONAL CENTER</b>	Sputnik V	Russian NRA	Human Adenovirus Vector-based Covid-19 vaccine	Additional information submitted	Several meetings held.	Rolling submission of clinical data started 09 Feb and additional data (CMC) still awaited.	Clinical review ongoing	Will be determined when CMC data is submitted
10.	 <b>康希诺生物</b> CansinoBio	Ad5-nCoV	NMPA	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	✓	✓	Rolling data starting April 2021		
11.	 <b>NOVAVAX</b>		EMA	No pre-submission meeting yet.	Submitted EOI on 23 Feb	To be planned			
12.	Vector State Research Centre of Virology and Biotechnology	EpiVacCorona	Russian NRA	Peptide antigen	Letter received not EOI. Reply sent on 15/01/2021				
13.	Zhifei Longcom, China	Recombinant Novel Coronavirus Vaccine (CHO Cell)	NMPA	Recombinant protein subunit	Response to 2 <sup>nd</sup> EOI sent 29 Jan 2021. Additional information requested.				
14.	IMBCAMS, China	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)	NMPA	Inactivated	Not accepted, still under initial development				
15.	 <b>Sinopharm</b> / <b>WIBP</b> <sup>1</sup>	Inactivated SARS-CoV-2 Vaccine (Vero Cell)	NMPA	Inactivated, produced in Vero cells					

<sup>1</sup> Beijing Bio-Institute of Biological Products Co-Ltd

<sup>2</sup> Wuhan Institute of Biological Products Co Ltd

\* Dossier Submission dates: more than one date is possible because of the rolling submission. Dossier is accepted for submission after screening of received submission

\*\* Status of assessment: 1. Under screening; 2. Under assessment; 3. Waiting responses from the applicant. 4. Risk-benefit decision 5. Final decision made

\*\*\* Anticipated decision date: this is only an estimate because it depends on when all the data is submitted under rolling submission and when all the responses to the assessors' questions are submitted.



## UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 6 Mar 2021

An overview of information collected from publicly announced bilateral and multilateral supply agreements [Agreements view from 2021-02-19 to date]

Number of vaccines approved for use

13

Reported global vaccine production volumes in 2021

20bn

Number of secured vaccine doses

10.2bn

Number of doses secured and optioned for the COVAX facility  
3.56bn\*

Range of reported vaccine price per dose

\$2.19 - \$44

Deal date	Recipient	Deal type	Vaccine name	Vaccine developer	Manufacturer
2021-02-19	African Union	Multilateral purchase	Sputnik V	Gamaleya Research Institute	Gamaleya Research Institute
2021-02-19	Cambodia	Government purchase	Covishield	AstraZeneca	Serum Institute of India
2021-02-19	Sri Lanka	Government purchase	Covishield	AstraZeneca	Serum Institute of India
2021-02-24	Honduras	Government purchase	AZD1222	AstraZeneca	AstraZeneca
2021-02-24	Honduras	Government purchase	Sputnik V	Gamaleya Research Institute	Gamaleya Research Institute
2021-02-24	Ukraine	Government purchase	BNT-162	Pfizer/BioNTech	Pfizer/BioNTech
2021-02-25	Argentina	Government purchase	BBIBP-CorV	CNBG	CNBG
2021-02-25	Macao	Government purchase	BNT-162	Pfizer/BioNTech	Fosun Pharma
2021-02-25	Ecuador	Government purchase	CoronaVac	Sinovac	Sinovac
2021-02-26	Canada	Government purchase	Covishield	AstraZeneca	Serum Institute of India

.....  
.....

### Our World in Data

#### Coronavirus (COVID-19) Vaccinations – Fully Vaccinated Population Percentage

Our World in Data and the SDG-Tracker are collaborative efforts between researchers at the University of Oxford, who are the scientific editors of the website content; and the non-profit organization [Global Change Data Lab](#), who publishes and maintains the website and the data tools that make our work possible. At the University of Oxford we are based at the [Oxford Martin Programme on Global Development](#).

Research and data: Hannah Ritchie, Esteban Ortiz-Ospina, Diana Beltekian, Edouard Mathieu, Joe Hasell, Bobbie Macdonald, Charlie Giattino, and Max Roser


Web development: Breck Yunits, Ernst van Woerden, Daniel Gavrilov, Matthieu Bergel, Shahid Ahmad, Jason Crawford, and Marcel Gerber

## Share of the population fully vaccinated against COVID-19, Mar 5, 2021

Share of the total population that have received all doses prescribed by the vaccination protocol. This data is only available for countries which report the breakdown of doses administered by first and second doses.

Our World  
in Data

+ Add country



Source: Official data collated by Our World in Data - Last updated 6 March, 11:46 (London time)

CC BY

Jan 3, 2021 Mar 5, 2021

.....  
.....

## U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

:: [COVID Data Tracker](#) Friday, March 6, 2021

### COVID-19 Vaccinations in the United States

Overall US COVID-19 Vaccine | Deliveries and Administration; Maps, charts, and data provided by the CDC, updated daily by 8 pm ET<sup>†</sup>

Represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

Total Vaccine Doses		People Vaccinated	
		Receiving 1 or More Doses	Receiving 2 Doses
Delivered	116,355,405	Total	57,358,849
Administered	87,912,323	% of Total Population	17.3%
Learn more about the distribution of vaccines.		Population ≥ 18 Years of Age	57,304,489
		% of Population ≥ 18 Years of Age	22.5%
			29,776,160
			9%
			29,755,823
			11.7%
		Read more about how these data are reported.	

CDC | Data as of: Mar 06 2021 6:00am ET | Posted: Mar 6 2021 12:24PM ET



## **White House [U.S.]**

### **Briefing Room**

#### **Fact Sheet: The U.S. Response to Ebola Outbreaks in West and East Africa**

March 05, 2021 • Statements and Releases

#### **Press Briefing by White House COVID-19 Response Team and Public Health Officials**

March 05, 2021 • Press Briefings

#### **Press Briefing by White House COVID-19 Response Team and Public Health Officials**

March 03, 2021 • Press Briefings

#### **Remarks by President Biden on the Administration's COVID-19 Vaccination Efforts**

March 02, 2021 • Speeches and Remarks

#### **Press Briefing by White House COVID-19 Response Team and Public Health Officials**

March 01, 2021 • Press Briefings

#### **Biden Administration Announces Historic Manufacturing Collaboration Between Merck and Johnson & Johnson to Expand Production of COVID-19 Vaccines**

*President Biden Invokes Defense Production Act to Support Measures to Accelerate Vaccine Development*

March 2, 2021

President Biden announced today that his Administration has helped forge a historic manufacturing collaboration between two of the largest U.S. health care and pharmaceutical companies, Merck and Johnson & Johnson (J&J), to expand production of J&J's COVID-19 vaccine. The collaboration will increase manufacture of vaccine drug substance, as well as its fill-finish capacity – two of the biggest bottlenecks facing J&J in the production of its vaccine.

**The U.S. Department of Health and Human Services (HHS) will collaborate with Merck to repurpose some of its existing Merck facilities for rapid large-scale manufacturing of vaccines and therapeutics for use in public health emergencies including the current pandemic. The facilities will be available to private sector partners working with the federal government on the COVID-19 response or to produce Merck products against COVID-19. Janssen Pharmaceuticals, part of Johnson & Johnson, will be the first federal partner to use repurposed Merck facilities to manufacture COVID-19 vaccine. Merck will use two of its facilities to produce drug substance, formulate and fill vials of J&J's vaccine.**

Consistent with the Administration's mission to ensure that the United States has sufficient long term sustainable capacity to manufacture vaccines, the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), **will leverage the Defense Production Act to provide an initial investment of \$105 million in funding for Merck, at the Administration's request, to convert, upgrade and equip Merck facilities to the standards necessary to safely manufacture the vaccine.** The company will address all the necessary qualification and validation activities needed for the facilities to be used for large-scale manufacturing.

To further accelerate production of the J&J vaccine, President Biden also announced he has invoked the Defense Production Act to expedite materials in vaccine production, such as equipment, machinery

and supplies like single use bags, and he has directed the Department of Defense (DOD) to provide daily logistical support to strengthen J&J's efforts. With the urging and assistance of the Administration, J&J also will begin operating its manufacturing facilities 24/7 to maximize production output.

These efforts will contribute to J&J's ability to accelerate delivery of their vaccine doses from 100 million doses by the end of June to at or near 100 million doses by the end of May. **In the long term, these actions will ultimately double J&J's U.S. capacity to produce drug substance and increase the U.S. capacity for fill-finish.**

.....  
.....

## **Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

### **News: EMA starts rolling review of the Sputnik V COVID-19 vaccine**

Last updated: 04/03/2021

EMA's human medicines committee (CHMP) has started a rolling review of Sputnik V (Gam-COVID-Vac), a COVID-19 vaccine<sup>1</sup> developed by Russia's Gamaleya National Centre of Epidemiology and Microbiology. The EU applicant for this medicine is R-Pharm Germany GmbH.

The CHMP's decision to start the rolling review is based on results from laboratory studies and clinical studies in adults. These studies indicate that Sputnik V triggers the production of antibodies and immune cells that target the SARS-CoV-2 coronavirus and may help protect against COVID-19.

EMA will evaluate data as they become available to decide if the benefits outweigh the risks. The rolling review will continue until enough evidence is available for formal marketing authorisation application.

EMA will assess Sputnik V's compliance with the usual EU standards for effectiveness, safety and quality...

### **News: EMA and Health Canada publish clinical data used to support their authorisations of the Moderna COVID-19 vaccine**

Last updated: 02/03/2021

Openness and transparency are key to building confidence in COVID-19 vaccines. Today, EMA and Health Canada collaboratively published the full clinical data reviewed as part of their authorisations of the Moderna COVID-19 vaccine.

This international partnership highlights the shared commitment of both organisations to ensure the public has as much information as possible to make decisions regarding vaccination. Increasing access to clinical data can also have widespread benefits for the health care system and the research community. EMA and Health Canada are the only two jurisdictions in the world publishing this comprehensive information.

"With the publication of the data package for Moderna's COVID-19 vaccine, we are publishing the clinical reports that we assessed in support of the authorisation of this vaccine, and going forward, we will continue with this open data approach for all other COVID-19 vaccines," said Emer Cooke, EMA's Executive Director. "EMA and Health Canada's joint commitment to openness and transparency will support global research, allow for public scrutiny and reinforce society's trust in COVID-19 vaccines as mass vaccination campaigns continue to be rolled out across the EU, Canada and the rest of the world."...

.....

.....

## **Africa: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

### **UNICEF**

*Press release* 03/05/2021

#### **[More than 1.7 million COVID-19 vaccines arrive in the Democratic Republic of Congo](#)**

*Press release* 03/03/2021

#### **[Sudan receives first delivery of COVID-19 vaccines with over 800,000 doses](#)**

Sudan becomes first country in the Middle East and North Africa to receive vaccines via the COVAX Facility

*Press release* 03/03/2021

#### **[340,000 doses of COVAX vaccines due in Rwanda today](#)**

Air freight carrying the AstraZeneca/Oxford SII vaccines supplied through the COVAX Facility arrives in Kigali. Pfizer-BioNTech vaccines expected to arrive later today.

.....

.....

## **Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

### **Russia: Sputnik V – “the first registered COVID-19 vaccine”**

<https://sputnikvaccine.com/newsroom/pressreleases/>

*Press Releases*

#### **[Sputnik V authorized in Iraq](#)**

Press release, 04.03.2021

#### **[Sputnik V authorized in Laos](#)**

Press release, 04.03.2021

#### **[Sputnik V authorized in Sri Lanka](#)**

Press release, 04.03.2021

#### **[EMA starts rolling review of Sputnik V](#)**

Press release, 04.03.2021

#### **[Sputnik V approved for use in Angola, Congo and Djibouti](#)**

Press release, 03.03.2021

#### **[Sputnik V approved for use in Slovakia](#)**

Press release, 01.03.2021

.....

.....

## **India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

## **Indian Council for Medical Research (ICMR)**

<https://www.icmr.gov.in/media.html>

### **Phase 3 Clinical Trial of COVAXIN, developed by ICMR & Bharat Biotech, shows 81% efficacy**

*The results, evaluated by an independent data safety and monitoring board, show that the vaccine is well-tolerated and efficacious against SARS-CoV-2 across a wide range of age groups and variants in the country*

New Delhi, 3 March 2021: Phase 3 results of the COVAXIN, developed by Indian Council of Medical Research (ICMR) in partnership with Bharat Biotech International Limited (BBIL), has shown an interim vaccine efficacy of 81% in preventing Covid-19. The Phase 3 trial, jointly initiated by ICMR and BBIL in mid-November 2020, was conducted in a total of 25,800 individuals across 21 sites. The interim efficacy trend of 81%, analyzed as per the protocol approved by the DCGI, puts it at par with other global front-runner vaccines. "The bench-to-bedside journey of completely indigenous COVID-19 vaccine in less than 8 months' time showcases the immense strength of *Atmanirbhar Bharat* [self-reliant India] to fight the odds and stand tall in the global public health community. It is also a testament to India's emergence as a global vaccine superpower" said Dr. Balram Bhargava, Director General, ICMR. The COVAXIN is the first COVID-19 vaccine that has been developed completely in India...

.....  
.....

## **China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

### **National Medical Products Administration – PRC [to 6 Mar 2021]**

<http://english.nmpa.gov.cn/news.html>

*News*

#### **Sinopharm chairman says vaccines can protect against COVID variants**

2021-03-05

Early research shows that the inactivated COVID-19 vaccines produced by Sinopharm can provide protection against 10 mutated variants of SARS-CoV-2, including strains from the United Kingdom and South Africa, said Yu Qingming, Sinopharm's board chairman and a deputy to the National People's Congress.

#### **Output of Sinopharm COVID-19 vaccines to top 1 bln doses in 2021**

2021-03-04

China has put the inactivated COVID-19 vaccines developed by state-owned pharmaceutical firm Sinopharm into mass production and this year's output is expected to surpass 1 billion doses, Yu Qingming, chairman of Sinopharm Group, said on March 3.

#### **Over 5 mln get COVID-19 vaccine in Beijing**

2021-03-04

Over 5 million people in Beijing had received COVID-19 vaccines as of 2 pm on March 2, local authorities said.

#### **New vaccine to 'provide 2-year protection'**

2021-03-01

An adenovirus vector vaccine against COVID-19 by CanSino Biologics is projected to provide protection for two years if a booster shot is administered, said a scientist who played a key role in the vaccine's development.

.....  
.....

## **COVID Vaccine Developer Announcements**

### **Moderna Announces Supply Agreement to Provide 13 Million Doses of COVID-19 Vaccine Moderna to the Philippines**

March 06, 2021

### **Moderna Announces New Drug Application Submitted to Import and Distribute Moderna's COVID-19 Vaccine Candidate in Japan**

March 04, 2021

### **Merck to Help Produce Johnson & Johnson's COVID-19 Vaccine; BARDA to Provide Merck With Funding to Expand Merck's Manufacturing Capacity for COVID-19 Vaccines and Medicines**

March 02, 2021

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today it has entered into multiple agreements to support efforts to expand manufacturing capacity and supply of SARS-CoV-2/COVID-19 medicines and vaccines. The Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), will provide Merck with funding of up to \$268.8 million to adapt and make available a number of existing manufacturing facilities for the production of SARS-CoV-2/COVID-19 vaccines and medicines. Merck has also entered into agreements with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to support the manufacturing and supply of Johnson & Johnson's SARS-CoV-2/COVID-19 vaccine. Merck will use its facilities in the United States to produce drug substance, formulate and fill vials of Johnson & Johnson's vaccine.

"We are steadfast in our commitment to contribute to the global response to the pandemic as part of the remarkable efforts of the entire medical and scientific community," said Mike Nally, executive vice president, Human Health at Merck. "This funding from BARDA will allow us to accelerate our efforts to scale up our manufacturing capacity to enable timely delivery of much needed medicines and vaccines for the pandemic."

Under the terms of the BARDA agreement, Merck will adapt and make available some of the company's existing manufacturing sites to accelerate manufacturing efforts for SARS-CoV-2/COVID-19 vaccines and medicines. This funding is in addition to Merck's continued investment in its global vaccines manufacturing network as part of its planned capital investments of more than \$20 billion from 2020 through the end of 2024...

.....  
.....

## COVID Vaccination: Incentives/Mandates/Passports

### Marriott International to Provide Associates Financial Award for COVID-19 Vaccination

BETHESDA, Md., March 4, 2021 /PRNewswire/ -- Marriott International, Inc. (NASDAQ: [MAR](#)) today announced it has created the Vaccination Care Program, which will provide a financial award to U.S. and Canadian associates at its managed properties who get vaccinated for COVID-19. Employees will receive the equivalent of four hours of pay upon completion of the vaccination...

### EU to propose Covid-19 vaccine passports in March

01/03/2021 - text by: FRANCE 24

The European Commission will present a proposal in March on creating an EU-wide digital vaccination passport, an issue that has divided member states, Commission chief Ursula von der Leyen said on Monday.

"We will submit a legislative proposal in March," [von der Leyen](#) told German conservative lawmakers during a video conference on Monday.

With vaccinations now well under way, governments are increasingly seeing vaccine "passports" – or other forms of [Covid-19](#) status certificates – as a way out of the cycles of shutdowns and curfews that have ground travel to a near halt.

The certificates would enable people to present proof of vaccination and thus skip quarantine protocols when arriving in a new country.

Greece unveiled a digital vaccination certificate in February for those who have received two doses of the vaccine.

Other countries that are currently issuing or asking for vaccine certificates include the Czech Republic, Poland, Italy, Spain and Portugal...

.....  
.....

## Emergencies

### **POLIO**

*Public Health Emergency of International Concern (PHEIC)*

### Polio this week as of 03 March 2021

***Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):***

- :: Afghanistan:** one cVDPV2 case and nine cVDPV2 positive environmental samples
- :: Pakistan:** three WPV1 environmental samples, three cVDPV2 cases and 10 cVDPV2 positive environmental samples
- :: Egypt:** two cVDPV2 positive environmental samples
- :: Ethiopia:** one cVDPV2 case and one positive environmental sample
- :: Liberia:** three cVDPV2 positive environmental samples
- :: South Sudan:** seven cVDPV2 cases
- :: Tajikistan:** one cVDPV2 positive environmental sample

.....  
.....

## WHO/OCHA Emergencies

### **Editor's Note:**

Continuing with this edition, we include information about the last apparent update evident on the WHO emergency country webpages, recognizing almost universal and significant interims since last update regardless of the level of the emergency listed.

### **WHO Grade 3 Emergencies** [to 6 Mar 2021]

Democratic Republic of the Congo - *No new digest announcements identified [Last apparent update: 12 Jan 2021]*

Mozambique floods - *No new digest announcements identified [Last apparent update: 3 November 2020]*

Nigeria - *No new digest announcements identified [Last apparent update: 29 Jun 2020]*

Somalia - *No new digest announcements identified [Last apparent update: 17 July 2020]*

South Sudan - *No new digest announcements identified [Last apparent update: 4 February 2020]*

Syrian Arab Republic - *No new digest announcements identified [Last apparent update: 24 October 2020]*

Yemen - *No new digest announcements identified [Last apparent update: 30 June 2020]*

.....

### **WHO Grade 2 Emergencies** [to 6 Mar 2021]

#### **Angola**

:: Angola becomes the first country in Eastern and Southern Africa region to receive COVAX Vaccines... 02 March 2021

Angola today received 624,000 doses of the AstraZeneca-Oxford vaccine from the Sérum Institute of India as part of the COVAX initiative, which aims to ensure the equitable distribution of vaccines against COVID-19 worldwide.

#### **Burkina Faso**

:: Au Burkina Faso, la « menace non perçue par les populations » de la résistance aux a... 05 mars 2021

#### **Malawi Floods**

:: Malawi receives first shipment of COVID-19 vaccines from COVAX 05 March 2021

#### **Niger**

:: La Première Dame du Niger Dr Lalla Malika Issoufou s'exprime sur l'impact de la COVI... 04 mars 2021

Afghanistan - *No new digest announcements identified [Last apparent update: 5 July 2020]*

Burundi - *No new digest announcements identified [Last apparent update: 04 July 2019]*

Cameroon - *No new digest announcements identified [Last apparent update: 22 August 2019]*

Central African Republic - *No new digest announcements identified [Last apparent update: 12 June 2018]*

Ethiopia - *No new digest announcements identified [Last apparent update: 22 August 2019]*

Iran floods 2019 - *No new digest announcements identified [Last apparent update: 2 March 2020]*

Iraq - *No new digest announcements identified [Last apparent update: 21 February 2020]*



Libya - *No new digest announcements identified [Last apparent update: 7 October 2019]*  
Measles in Europe - *No new digest announcements identified [Last apparent update: 16-12-2020]*  
MERS-CoV - *No new digest announcements identified [Last apparent update: 8 July 2019]*  
Mozambique - *No new digest announcements identified [Last apparent update: 03 November 2020]*  
Myanmar - *No new digest announcements identified [Last apparent update: 11 février 2021]*  
occupied Palestinian territory - *No new digest announcements identified [Last apparent update: 4 September 2019]*  
HIV in Pakistan - *No new digest announcements identified [Last apparent update: 27 August 2019]*  
Sao Tome and Principe Necrotizing Cellulitis (2017) - *No new digest announcements*  
Sudan - *No new digest announcements identified [Last apparent update: 24 June 2020]*  
Ukraine - *No new digest announcements identified [Last apparent update: 1 May 2019]*  
Zimbabwe - *No new digest announcements identified [Last apparent update: 10 May 2019]*

.....

#### **WHO Grade 1 Emergencies** [to 6 Mar 2021]

Chad - *No new digest announcements identified [Last apparent update: 30 June 2018]*  
Djibouti - *No new digest announcements identified [Last apparent update: 25 novembre 2020]*  
Kenya - *No new digest announcements identified [Last apparent update: 11 December 2020]*  
Mali - *No new digest announcements identified [Last apparent update: 3 May 2017]*  
Namibia - viral hepatitis - *No new digest announcements identified [Last apparent update: 20 July 2018]*  
Tanzania - *No new digest announcements identified [Last apparent update: 21 October 2020]*

.....

.....

#### **UN OCHA – L3 Emergencies**

*The UN and its humanitarian partners are currently responding to three 'L3' emergencies. This is the global humanitarian system's classification for the response to the most severe, large-scale humanitarian crises.*

##### **Syrian Arab Republic**

:: Syrian Arab Republic: COVID-19 Humanitarian Update No. 24 As of 3 March 2021

Yemen - *No new digest announcements identified*

.....

#### **UN OCHA – Corporate Emergencies**

*When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.*

##### **East Africa Locust Infestation**

:: Desert Locust situation update 3 March 2021

#### **COVID-19**

:: Coronavirus Disease (COVID-19): Weekly Epidemiological Update (2 March 2021)

*[See Week in Review above for detail]*

.....  
.....

**WHO & Regional Offices** [to 6 Mar 2021]

5 March 2021

News release

**[New WHO/IAEA publication provides guidance on radiotherapy equipment to fight cancer](#)**

5 March 2021

*Departmental news*

**[WHO publishes materials that aim to provide high-quality care to people affected by lymphatic filariasis](#)**

4 March 2021

*News release*

**[Rotavirus vaccines made available for use in humanitarian crises](#)**

*[See Milestones above for detail]*

4 March 2021

*Medical product alert*

**[Medical Product Alert N°1/2021: Falsified Vitamin A](#)**

3 March 2021

*Departmental news*

**[New WHO report on Human T-lymphotropic virus type 1 highlights strategies for its prevention and control](#)**

2 March 2021

*Statement*

**[COVAX publishes first round of allocations](#)**

2 March 2021

*News release*

**[WHO: 1 in 4 people projected to have hearing problems by 2050](#)**

1 March 2021

*Departmental news*

**[World Pharmacopoeias support public health during COVID-19 pandemic](#)**

1 March 2021

*News release*

**[First COVID-19 COVAX vaccine doses administered in Africa](#)**

.....

**[Weekly Epidemiological Record \[WER\] 5 March 2021, Vol. 96, No. 09, pp. 65–68](#)**

:: Performance of acute flaccid paralysis (AFP) surveillance and incidence of poliomyelitis, 2020

.....

## **WHO Regional Offices**

*Selected Press Releases, Announcements*

### **WHO African Region AFRO**

:: Niger's First Lady, Dr Lalla Malika Issoufou, speaks on COVID-19 impact on women 04 March 2021

### **WHO Region of the Americas PAHO**

*No new digest content identified*

### **WHO South-East Asia Region SEARO**

*No new digest content identified*

### **WHO European Region EURO**

:: WHO/Europe launches caregiver skills training in Kazakhstan to support children with neurodevelopmental delays 05-03-2021

:: Republic of Moldova prepares for COVID-19 vaccine deployment 04-03-2021

:: International Women's Day: the need to build back better, with women in the lead 04-03-2021

:: Inspiring change: women's leadership in health care is vital during the COVID-19 pandemic and beyond 04-03-2021

:: How healthy are children's eating habits? – WHO/Europe surveillance results 03-03-2021

### **WHO Eastern Mediterranean Region EMRO**

:: First COVID-19 vaccines arrive in Djibouti 6 March 2021

### **WHO Western Pacific Region**

*No new digest content identified*

.....

.....

## **CDC/ACIP [U.S.] [to 6 Mar 2021]**

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

*Latest News Releases, Announcements*

### **CDC to Require Airlines to Collect Contact Information from Passengers from DRC and Guinea**

Tuesday, March 2, 2021

## **MMWR News Synopsis Friday, March 5, 2021**

:: SARS-CoV-2 Infection Risk among Active Duty Military Members Deployed to a Field Hospital—New York City, April 2020

:: Estimated SARS-CoV-2 Seroprevalence Among Persons Aged <18 Years — Mississippi, May–September 2020

:: Community Transmission of SARS-CoV-2 at Three Fitness Facilities — Hawaii, June–July 2020 (Early Release February 24, 2021)

:: COVID-19 Outbreak Among Attendees of an Exercise Facility — Chicago, Illinois, August–September 2020 (Early Release February 24, 2021)

:: Reduction in COVID-19 Patients Requiring Mechanical Ventilation Following Implementation of a National COVID-19 Vaccination Program — Israel, December 2020–February 2021 (Early Release February 26, 2021)

:: The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021 (Early Release March 2, 2021)

.....

## **Coronavirus Disease 2019 (COVID-19)- CDC**

### *Selected Resources*

:: Overall US COVID-19 Vaccine Distribution and Administration Update as of Fri, 05 Mar 2021 06:00:00 EST Friday, March 05, 2021

:: The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine - United States, February 2021 Thursday, March 04, 2021

:: US COVID-19 Cases Caused by Variants Thursday, March 04, 2021

:: Media Statement from CDC Director Rochelle P. Walensky, MD, MPH, on Signing the Advisory Committee on Immunization Practices' Recommendation to Use Janssen's COVID-19 Vaccine in People 18 and Older Sunday, February 28, 2021

.....

.....

## **Africa CDC [to 6 Mar 2021]**

<http://www.africacdc.org/>

### *News*

**Africa CDC and EDCTP partner to train highly skilled epidemiologists and biostatisticians in Africa**

4 March 2021

.....

.....

## **China CDC**

<http://www.chinacdc.cn/en/>

*No new digest content identified.*

## **National Health Commission of the People's Republic of China [to 6 Mar 2021]**

<http://en.nhc.gov.cn/>

### *News*

**March 6: Daily briefing on novel coronavirus cases in China**

On March 5, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 10 new cases of confirmed infections.

## **National Medical Products Administration – PRC [to 6 Mar 2021]**

<http://english.nmpa.gov.cn/news.html>

### *News*

**Sinopharm chairman says vaccines can protect against COVID variants**

2021-03-05

*[See China above for detail]*

### **Output of Sinopharm COVID-19 vaccines to top 1 bln doses in 2021**

2021-03-04

*[See China above for detail]*

### **Over 5 mln get COVID-19 vaccine in Beijing**

2021-03-04

Over 5 million people in Beijing had received COVID-19 vaccines as of 2 pm on March 2, local authorities said.

### **New vaccine to 'provide 2-year protection'**

2021-03-01

*[See China above for detail]*

.....

.....

## **Organization Announcements**

### **Paul G. Allen Frontiers Group** [to 6 Mar 2021]

<https://alleninstitute.org/what-we-do/frontiers-group/news-press/>

*News*

*No new digest content identified.*

### **BARDA – U.S. Department of HHS** [to 6 Mar 2021]

<https://www.phe.gov/about/barda/Pages/default.aspx>

*BARDA News*

### **March 2, 2021: Biden Administration Announces Historic Manufacturing Collaboration Between Merck and Johnson & Johnson to Expand Production of COVID-19 Vaccines**

*[See COVID above for detail]*

### **BMGF - Gates Foundation** [to 6 Mar 2021]

<http://www.gatesfoundation.org/Media-Center/Press-Releases>

*Press Releases and Statements*

*No new digest content identified.*

### **Bill & Melinda Gates Medical Research Institute** [to 6 Mar 2021]

<https://www.gatesmri.org/>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*No new digest content identified.*

**CARB-X** [to 6 Mar 2021]

<https://carb-x.org/>

*News*

03.01.2021 |

**[CARB-X is funding GSK to support the development of two unique vaccine projects that aim to prevent serious bacterial infections killing thousands worldwide each year](#)**

CARB-X is funding the GSK Biologicals and its affiliate GSK Vaccines Institute for Global Health (GVGH), based in Siena, Italy, to develop new vaccines to prevent serious infections caused by two different pathogens. Together, the two awards could be worth potentially more than \$18 million if project milestones are met, subject to available funding.

**Center for Vaccine Ethics and Policy – GE2P2 Global Foundation** [to 6 Mar 2021]

<https://centerforvaccineethicsandpolicy.net/>

*News/Analysis/Statements*

:: Past weekly editions of ***Vaccines and Global Health: The Week in Review*** are [available here](#).

:: A new edition of ***Informed Consent: A Monthly Digest*** is [now posted here](#) and via a [PDF](#).

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 6 Mar 2021]

<http://cepi.net/>

*Latest News*

**[Going universal: The search for an all-in-one coronavirus vaccine](#)**

Instead of working to make vaccines against each unique coronavirus or variant, what if we could provide broad protection across the field through an all-in-one coronavirus shot?

01 Mar 2021

**[First COVID-19 COVAX vaccine doses administered in Africa](#)**

Côte d'Ivoire and Ghana began COVID-19 vaccination campaigns aimed at protecting healthcare workers. A further 11 million COVAX doses are expected to be delivered over the next seven days.

01 Mar 2021

**DARPA – Defense Advanced Research Projects Agency** [to 6 Mar 2021]

<https://www.darpa.mil/>

*News*

*No new digest content identified.*

**[Duke Global Health Innovation Center](#)** [to 6 Mar 2021]

<https://dukeghic.org/>

*Launch and Scale Speedometer*

*No new digest content identified.*

**EDCTP** [to 6 Mar 2021]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

04 March 2021

**[EDCTP and Africa CDC partner to train highly skilled epidemiologists and biostatisticians in Africa](#)**

**Emory Vaccine Center** [to 6 Mar 2021]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Commission** [to 6 Mar 2021]

<http://europa.eu/rapid/search-result.htm?query=18&locale=en&page=1>

*Latest*

*No new digest content identified.*

**European Medicines Agency** [to 6 Mar 2021]

<http://www.ema.europa.eu/ema/>

*News & Press Releases*

**[News: EMA starts rolling review of the Sputnik V COVID-19 vaccine](#)**

Last updated: 04/03/2021

*[See COVID above for detail]*

**[News: EMA and Health Canada publish clinical data used to support their authorisations of the Moderna COVID-19 vaccine](#)**

Last updated: 02/03/2021

*[See COVID above for detail]*

**European Vaccine Initiative** [to 6 Mar 2021]

<http://www.euvaccine.eu/>

*Latest News*

*No new digest content identified.*

**FDA** [to 6 Mar 2021]

<https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm>

*Press Announcements / Selected Details*

**[March 5, 2021 - Coronavirus \(COVID-19\) Update: March 5, 2021](#)**

**[March 2, 2021 - Coronavirus \(COVID-19\) Update: March 2, 2021](#)**

**FDA - COVID-19 Vaccines** [to 6 Mar 2021]



[www.fda.gov/covid19vaccines](http://www.fda.gov/covid19vaccines)

*News and Updates; Upcoming Events*

**FDA Statement on Vaccines and Related Biological Products Advisory Committee Meeting**

02/26/2021

Following today's positive advisory committee meeting outcome regarding the Janssen Biotech Inc. COVID-19 Vaccine, the FDA has informed the sponsor that it will rapidly work toward finalization and issuance of an emergency use authorization.

**Fondation Merieux** [to 6 Mar 2021]

<http://www.fondation-merieux.org/>

*News, Events*

*Mérieux Foundation co-organized event*

**Advanced Course on Diagnostics (ACDx): Special Edition on COVID-19**

March 15 - 17, 2021 - Virtual

**Gavi** [to 6 Mar 2021]

<https://www.gavi.org/>

*News Releases*

2 March 2021

**COVAX publishes first round of allocations**

1 March 2021

**First COVID-19 COVAX vaccine doses administered in Africa**

*[See COVID above for detail on these announcements]*

**GHIT Fund** [to 6 Mar 2021]

<https://www.ghitfund.org/newsroom/press>

*GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that*  
*Press Releases*

*No new digest content identified.*

**Global Fund** [to 6 Mar 2021]

<https://www.theglobalfund.org/en/news/>

*News & Stories*

*News*

**Global Fund and Fondation CHANEL Form New Partnership to Advance Women's Health in Western and Central Africa**

04 March 2021

The Global Fund and Fondation CHANEL have signed a new agreement to set up a civil society-led fund to strengthen women's and girls' engagement in developing health policies, including Global Fund-related processes, in western and central Africa. The partnership, worth US\$1.5 million, will run for three years starting in Senegal, Burkina Faso, and Côte d'Ivoire.

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 6 Mar 2021]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified.*

**Hilleman Laboratories** [to 6 Mar 2021]

<http://www.hillemanlabs.org/>

*No new digest content identified.*

**Human Vaccines Project** [to 6 Mar 2021]

<http://www.humanvaccinesproject.org/media/press-releases/>

*HVP COVID Report*

**[Universal Coronavirus Vaccines: Invest Now or Pay Later](#)**

Wayne Koff, Ph.D.

Founding President and CEO

The Human Vaccines Project

**IAVI** [to 6 Mar 2021]

<https://www.iavi.org/newsroom>

*PRESS RELEASES/FEATURES*

March 5, 2021

**[International Women's Day 2021](#)**

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*\*News*

*Press Releases/Announcements*

*No new digest content identified.*

**IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

**IFRC** [to 6 Mar 2021]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Selected Press Releases, Announcements*

*Middle East and North Africa, Syria*

**Syria crisis: 10 years on, humanitarian situation is worse than ever**

The daily suffering of Syrians is worse now than it has been at nearly any point throughout the decade-long conflict that has ravaged the country. This is the sobering message delivered today by three senior Red Cross and Red Crescent officials as Syria enters the second decade of a relentless crisis.

4 March 2021

**Institut Pasteur** [to 6 Mar 2021]

<https://www.pasteur.fr/en/press-area>

*No new digest content identified.*

**IRC International Rescue Committee** [to 6 Mar 2021]

<http://www.rescue.org/press-release-index>

*Media highlights [Selected]*

*Press Release*

**New IRC report: A decade of attacks on health care in Syria**

March 3, 2021

*IRC survey of 237 people + 74 health workers on 10th anniversary of the Syria conflict*

:: 81% of surveyed health workers said they had a coworker or patient who had been injured or killed due to an attack

:: 77% had witnessed an average of four attacks on health care - some had witnessed as many as 20 over the course of the war

:: 68% were inside a health facility when it was attacked

:: 59% of civilians surveyed had been directly impacted by an attack on a health facility during the course of the conflict

:: 49% fear accessing health care as a result of attacks

:: 8 in 10 indicate having fled home at least 6 times during the conflict - some as many as 25 times

**IVAC** [to 6 Mar 2021]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

**IVI** [to 6 Mar 2021]

<http://www.ivi.int/>

*Selected IVI News, Announcements, Events*

*No new digest content identified.*

**JEE Alliance** [to 6 Mar 2021]

<https://www.jeealliance.org/>

Selected News and Events  
*No new digest content identified.*

**Johns Hopkins Center for Health Security** [to 6 Mar 2021]

<https://www.centerforhealthsecurity.org/news/center-news/>

*Center News*

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 6 Mar 2021]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*DRC Ebola outbreaks*

[\*\*DRC's twelfth Ebola outbreak\*\*](#)

Crisis Update 5 Mar 2021

*Syria*

[\*\*A decade of war in Syria: 10 years of increasing humanitarian needs\*\*](#)

Project Update 3 Mar 2021

**National Vaccine Program Office - U.S. HHS** [to 6 Mar 2021]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

*No new digest content identified.*

**NIH** [to 6 Mar 2021]

<http://www.nih.gov/news-events/news-releases>

*News Releases*

[\*\*NIH-Sponsored ACTIV-3 Clinical Trial Closes Enrollment into Two Sub-Studies\*\*](#)

March 4, 2021 — ACTIV-3 is a master protocol designed to allow for the study of multiple investigational agents compared to placebo in adults hospitalized with COVID-19.

[\*\*NIH halts trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms\*\*](#)

March 2, 2021 — Study shows the treatment is safe, but provides no significant benefit in this group.

[\*\*NIH effort seeks to understand MIS-C, range of SARS-CoV-2 effects on children\*\*](#)

March 2, 2021 — Program to investigate why some children are at greater risk for SARS-CoV-2 infection than others.

**UN OCHA** Office for the Coordination of Humanitarian Affairs [to 6 Mar 2021]

<https://www.unocha.org/>

*Selected Research, Announcement*

*No new digest content identified.*

**PATH** [to 6 Mar 2021]

<https://www.path.org/media-center/>

*Press Releases*

*No new digest content identified.*

**Sabin Vaccine Institute** [to 6 Mar 2021]

<http://www.sabin.org/updates/pressreleases>

*Statements and Press Releases*

*No new digest content identified.*

**UNAIDS** [to 6 Mar 2021]

<http://www.unaids.org/en>

*Selected Press Releases/Reports/Statements*

3 March 2021

[From HIV survivor to COVID-19 responder](#)

2 March 2021

[Faith-based project against paediatric HIV launched in Côte d'Ivoire](#)

1 March 2021

[US\\$ 64 million to respond to HIV, TB and malaria in Congo](#)

**UNDP** United Nations Development Programme [to 6 Mar 2021]

<http://www.undp.org/content/undp/en/home/presscenter.html>

*Latest from News Centre*

[UNDP calls for temporary basic income to help world's poorest women cope with effects of COVID-19 pandemic](#)

A temporary basic income (TBI) given specifically to hundreds of millions of women in the world's developing countries could prevent rising poverty and widening gender inequalities during the COVID-19... Posted on March 4, 2021

**UNESCO** [to 6 Mar 2021]

<http://en.unesco.org/news>

*Selected Latest News*

*No new digest content identified.*

**UNHCR** Office of the United Nations High Commissioner for Refugees [to 6 Mar 2021]

<http://www.unhcr.org/en-us/media-centre.html>

*Selected Announcements*

*No new digest content identified.*

**UNICEF** [to 6 Mar 2021]

<https://www.unicef.org/media/press-releases>

*Selected Press releases, Statements*

*Press release 03/05/2021*

**More than 1.7 million COVID-19 vaccines arrive in the Democratic Republic of Congo**

*Press release 03/03/2021*

**At least 1 in 7 children and young people has lived under stay-at-home policies for most of the last year, putting mental health and well-being at risk**

As we approach the one-year anniversary of the pandemic, UNICEF urges greater investment in mental health services

*Press release 03/03/2021*

**Sudan receives first delivery of COVID-19 vaccines with over 800,000 doses**

Sudan becomes first country in the Middle East and North Africa to receive vaccines via the COVAX Facility

*Press release 03/03/2021*

**340,000 doses of COVAX vaccines due in Rwanda today**

Air freight carrying the AstraZeneca/Oxford SII vaccines supplied through the COVAX Facility arrives in Kigali. Pfizer-BioNTech vaccines expected to arrive later today.

*Statement 03/02/2021*

**Remarks by Henrietta Fore, UNICEF Executive Director at COVAX media briefing on first deliveries and first round of allocations**

*As prepared for delivery*

*[See COVID above for detail]*

*Statement 03/02/2021*

**COVAX publishes first round of allocations**

**Unitaid** [to 6 Mar 2021]

<https://unitaid.org/>

*Featured News*

*No new digest content identified.*

**Vaccination Acceptance Research Network (VARN)** [to 6 Mar 2021]

<https://vaccineacceptance.org/news.html#header1-2r>

*Announcements*

*No new digest content identified.*

**Vaccine Confidence Project** [to 6 Mar 2021]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

### **Coronavirus global impact**

Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

### **Vaccine Education Center – Children’s Hospital of Philadelphia** [to 6 Mar 2021]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

*No new digest content identified.*

### **Wellcome Trust** [to 6 Mar 2021]

<https://wellcome.ac.uk/news>

*Q&A*

Anna Mouser, Jeremy Farrar

### **Why we need fair global vaccine allocation to end Covid-19**

2 March 2021

*Explainer*

### **Why is a global Covid-19 vaccine rollout vital?**

2 March 2021

### **The Wistar Institute** [to 6 Mar 2021]

<https://www.wistar.org/news/press-releases>

*Press Releases*

*No new digest content identified.*

### **WFPHA: World Federation of Public Health Associations** [to 6 Mar 2021]

<https://www.wfpha.org/>

*Latest News*

### **WFPHA Has Joined the WHO’s Campaign for #VaccinEquity**

Mar 4, 2021

WFPHA Has Joined the WHO's Campaign for #VaccinEquityHealth workers have been at the frontline of the COVID-19 pandemic response. In January 2021, the Director-General of the World Health Organization (WHO) has called all countries to work together...

### **Coalition of International NGOs Call for Equitable Access for Vaccines and Treatment during COVID-19 Pandemic**

Mar 4, 2021

*Coalition of International NGOs Call for Equitable Access for Vaccines and Treatment during COVID-19 Pandemic*

Around the world, governments are struggling to find ways to work together and control the spread of COVID-19. The virus does not recognize...

*[See COVID above for detail]*

### **Call to Governments to Support the TRIPS Waiver Proposal to End the COVID-19 Pandemic**



Mar 1, 2021

*Call to Governments to Support the TRIPS Waiver Proposal to End the COVID-19 Pandemic*

The time is now to stop vaccine nationalism, private profiteering, and stand in solidarity with the world for health equity and human rights. WFPHA joins the...

**World Bank** [to 6 Mar 2021]

<http://www.worldbank.org/en/news/all>

*Selected News, Announcements*

**World Bank Bond Expands Support to COVID-19 Resilience Through the United Nations Children's Fund (UNICEF)**

Washington, DC, March 4, 2021—The World Bank (International Bank for Reconstruction and Development or IBRD) has issued a US\$100 million 5-year bond which both supports IBRD's ongoing sustainable development...

Date: March 04, 2021 Type: Press Release

*[See COVID above for detail]*

**Reversing the Disproportionate Impact of the Pandemic on Female Workers in Latin America and the Caribbean**

Women were 44 percent more likely to lose their jobs in the crisis than men. Permanent job losses affected one in five women according to a new World Bank report. WASHINGTON, March 4, 2021 – Working women...

Date: March 04, 2021 Type: Press Release

**Future of Cities Will Shape Post-COVID-19 World**

Cities have a once -in-a-lifetime chance to leverage the pandemic and build back in a resilient, inclusive and sustainable way

Date: March 02, 2021 Type: Feature Story

**World Customs Organization – WCO** [to 6 Mar 2021]

<http://www.wcoomd.org/>

*Latest News – Selected Items*

*No new digest content identified.*

**World Organisation for Animal Health (OIE)** [to 6 Mar 2021]

<https://www.oie.int/en/for-the-media/press-releases/2021/>

*Press Releases*

*No new digest content identified.*

.....

**ARM [Alliance for Regenerative Medicine]** [to 6 Mar 2021]

[Press Releases - Alliance for Regenerative Medicine \(alliancerm.org\)](http://alliancerm.org)

*Press Releases*

*No new digest content identified.*

**BIO** [to 6 Mar 2021]  
<https://www.bio.org/press-releases>  
*Press Releases*  
*No new digest content identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 6 Mar 2021]  
<http://www.dcvmn.org/>  
*News; Upcoming events*  
*No new digest content identified.*

**ICBA – International Council of Biotechnology Associations** [to 6 Mar 2021]  
<https://internationalbiotech.org/news/>  
*News*  
*No new digest content identified.*

**IFPMA** [to 6 Mar 2021]  
<http://www.ifpma.org/resources/news-releases/>  
*Selected Press Releases, Statements, Publications*  
*No new digest content identified.*

**PhRMA** [to 6 Mar 2021]  
<http://www.phrma.org/>  
*Selected Press Releases, Statements*  
*No new digest content identified.*

\* \* \* \*

### ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

**AJOB Empirical Bioethics**  
Volume 12, 2020 Issue 1  
<https://www.tandfonline.com/toc/uabr21/current>  
[Reviewed earlier]

**AMA Journal of Ethics**

Volume 23, Number 2: E83-211 Feb 2021

<https://journalofethics.ama-assn.org/issue/racial-and-ethnic-health-equity-us-part-2>

***Racial and Ethnic Health Equity in the US: Part 2***

Health equity is defined by the World Health Organization as the “absence of unfair and avoidable or remediable differences in health among social groups.” Domestically and globally, health inequity is not a historical accident. Inequity today is not *unfortunate*—that is, not a product of a mere turn of the proverbial cosmic wheel—but *unjust*—that is, generated by colonial, White supremacist policies and practices structured and maintained over time, forged to persist in hierarchies that serve some of us, our ancestors, and our descendants well and some of us, our ancestors, and our descendants ill. This first of a 2-part theme issue focuses specifically on racial and ethnic inequity in morbidity, mortality, and access to services that are endemic to American life. We investigate health inequity as a product of transgenerational patterns of oppression that must be remediated by all of us compassionately and more deliberately and quickly than they were created.

**American Journal of Infection Control**

March 2021 Volume 49 Issue 3 p281-408

<http://www.ajicjournal.org/current>

[Reviewed earlier]

**American Journal of Preventive Medicine**

March 2021 Volume 60 Issue 3 p311-452

<http://www.ajpmonline.org/current>

[Reviewed earlier]

**American Journal of Public Health**

March 2021 111(3)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

**American Journal of Tropical Medicine and Hygiene**

Volume 104, Issue 1, January 2021

<http://www.ajtmh.org/content/journals/14761645/104/1>

[Reviewed earlier]

**Annals of Internal Medicine**

February 2021 Volume 174, Issue 2

<http://annals.org/aim/issue>

[Reviewed earlier]

## **Artificial Intelligence – An International Journal**

Volume 292 March 2021

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/292/suppl/C>

[Reviewed earlier]

## **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 6 Mar 2021)

[No new digest content identified]

## **BMJ Global Health**

March 2021 - Volume 6 - 3

<https://gh.bmj.com/content/6/3>

Commentary

**[Communicating COVID-19 vaccines: lessons from the dengue vaccine controversy in the Philippines](#)** (2 March, 2021)

Gideon Lasco, Vincen Gregory Yu

**[An urgent call to collect data related to COVID-19 and Indigenous populations globally](#)** (2 March, 2021)

Alistair Mallard, Maria Amalia Pesantes, Carol Zavaleta-Cortijo, James Ward

## **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 6 Mar 2021)

**[Regional differences in general practitioners' behaviours regarding influenza vaccination: a cross-sectional study](#)**

*The World Health Organization recommends vaccination rates of 75% against seasonal influenza for patients over 65 years old. In the 2013/2014 season, the German vaccination rates ranged between 14 and 65%. Thi...*

Authors: Jonathan Arlt, Kristina Flaegel, Katja Goetz and Jost Steinhäuser

Citation: BMC Health Services Research 2021 21:197

Content type: Research article

Published on: 4 March 2021

## **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 6 Mar 2021)

**[Antibiotic resistance in Pakistan: a systematic review of past decade](#)**

*During the last six decades, extensive use of antibiotics has selected resistant strains, increasing the rate of fatal infectious diseases, and exerting an economic burden on society. This situation is widely ...*

Authors: Hazrat Bilal, Muhammad Nadeem Khan, Tayyab Rehman, Muhammad Fazal Hameed and Xingyuan Yang

Citation: BMC Infectious Diseases 2021 21:244

Content type: Research article  
Published on: 6 March 2021

### **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 6 Mar 2021)

Research article

#### **Systematic review: bioethical implications for COVID-19 research in low prevalence countries, a distinctly different set of problems**

*A systematic review failed to identify articles relating to COVID-19 research ethics, specific to low prevalence countries. It shows that there is a significant gap in the literature that warrants further investigation. Common ethical principles were used to present a distinct set of challenges experienced by a country with a low prevalence of COVID-19. This unique perspective of some of the common ethical problems surrounding research, may help guide further discussion and guide research in similar countries.*

Authors: Tony Skapetis, Constance Law and Rohan Rodricks

Citation: BMC Medical Ethics 2021 22:22

Content type: Research article

Published on: 3 March 2021

#### **Facing new challenges to informed consent processes in the context of translational research: the case in CARPEM consortium**

*In the context of translational research, researchers have increasingly been using biological samples and data in fundamental research phases. To explore informed consent practices, we conducted a retrospective study on informed consent documents that were used for CARPEM's translational research programs. This review focused on detailing their form, their informational content, and the adequacy of these documents with the international ethical principles and participants' rights.*

Authors: Elise Jacquier, Pierre Laurent-Puig, Cécile Badoual, Anita Burgun and Marie-France Mamzer

Citation: BMC Medical Ethics 2021 22:21

Content type: Research article

Published on: 2 March 2021

### **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 6 Mar 2021)

[No new digest content identified]

### **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 6 Mar 2021)

[No new digest content identified]

### **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 6 Mar 2021)

### **Disparities in influenza vaccination: Arab Americans in California**

*Influenza vaccination among minoritized groups remains below federal benchmarks in the United States (US). We used data from the 2004–2016 California Health Interview Surveys (CHIS) to characterize influenza v...*

Authors: Rose-Marie Jungquist and Nadia N. Abuelezam

Citation: BMC Public Health 2021 21:443

Content type: Research article

Published on: 5 March 2021

### **Measles outbreak in complex emergency: estimating vaccine effectiveness and evaluation of the vaccination campaign in Borno State, Nigeria, 2019**

*From January to May 2019, large measles outbreaks affected Nigeria. Borno state was the most affected, recording 15,237 suspected cases with the state capital of Maiduguri having 1125 cases investigated and li...*

Authors: Anne Eudes Jean Baptiste, John Wagai, Richard Luce, Balcha Masresha, Don Klinkenberg, Irene Veldhuijzen, Joseph Oteri, Boubacar Dieng, Obianuju Caroline Ikeonu, Sule Meleh, Audu Musa, Fiona Braka, Susan Hahné, E. A. M. Sanders and Eelko Hak

Citation: BMC Public Health 2021 21:437

Content type: Research article

Published on: 4 March 2021

### **BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 6 Mar 2021)

[No new digest content identified]

### **BMJ Open**

March 2021 - Volume 11 - 3

<https://bmjopen.bmj.com/content/11/3>

### **Protocol: Evaluation of the decision-making process underlying the initial off-label use of vaccines: a scoping review protocol** (4 March, 2021)

Dieynaba Diallo, Caroline Quach

Vaccination has become a central part of public health prevention. Vaccines are introduced after licensure by national regulatory authorities, whereas recommendations for use of licensed vaccines are made by national or international advisory committees and may include off-label use. The methodological and decision-making processes that are used to assess novel initial off-label vaccine use are unclear. This review aims to examine the off-label assessment processes to map evidence and concepts used in the decision-making process and present a common approach between all recommendations and specifics of each decision.

Strengths and limitations of this study

:: Strengths of this review comprise the substantial significance of mapping the decision-making processes and methods used for off-label vaccine recommendations.

:: The use of recognised scoping review methodology.

:: A search strategy developed in collaboration with an experienced senior health research librarian.

:: Systematic screening and extraction of data independently conducted in duplicate.

:: Off-label vaccine use established practices, not published in an official form by national authorities, potentially represent a limitation for this review.

## **Bulletin of the World Health Organization**

Volume 99, Number 3, March 2021, 169-240

<https://www.who.int/bulletin/volumes/99/3/en/>

### **EDITORIALS**

#### **[The quality-of-care agenda in fragile, conflict-affected and vulnerable settings](#)**

— Matthew Neilson, Sheila Leatherman & Shamsuzzoha Syed

<http://dx.doi.org/10.2471/BLT.21.285627>

#### **[Coordinating COVID-19 vaccine deployment through the WHO COVID-19 Partners Platform](#)**

— M Anne Yu, Angela K Shen, Michael J Ryan & Linda Lucy Boulanger

<http://dx.doi.org/10.2471/BLT.21.285550>

...WHO, in collaboration with the United Nations (UN) Development Coordination Office, launched the WHO COVID-19 Partners Platform to operationalize the plan.<sup>6</sup> On this platform, for the first time, governments, UN agencies and partners can plan and coordinate, in real time, for an acute event. This innovative digital ecosystem operationalizes the nine pillars of the plan: country-level coordination, planning and monitoring; risk communication and community engagement; surveillance, rapid-response teams and case investigation; points of entry, international travel and transport; national laboratories; infection prevention and control; case management; operational support and logistics; and maintaining essential health services and systems.

The platform has facilitated actions within these initial nine strategic pillars and continues to do so.<sup>6</sup> As a tool for emergency management, the platform supports transparency, collaboration and efficiency for countries, UN agencies, implementing partners and donors in their COVID-19 response. At the core of the platform is a centralized digital environment where countries and partners, in the context of an outbreak, can: (i) develop and share plans; (ii) monitor and review implemented actions; (iii) cost plans, share resource needs, and request critical supplies; and (iv) view and track donor contributions. These four basic functionalities are fundamental to emergency response in every nation, regardless of whether resources come from the international community or are domestically available.

As of 4 February 2021, the platform has tracked 9.3 billion United States dollars (US\$) of requested resources and approximately US\$ 8 billion in donor contributions.<sup>6</sup> A total of 120 countries, areas and territories have integrated the platform into their emergency management cycle (disease prevention and mitigation, preparedness, response and recovery), supporting preparedness and response using a model that optimizes near real-time management of public health emergency needs and demands. The platform allows for rapid response in public health practice, provides a centralized hub to house information for decision-making, and brings stakeholders from across sectors within countries, including donors and key implementing partners, to collaborate using a common planning framework. The platform is accessible to and enabled by countries, regions and partners, and governed by the countries, who determine how to support their own needs.

Coordination is at the centre of the platform and critical to an effective response. In January 2021, a tenth pillar was added to the platform to support national deployment of COVID-19 vaccines when available...

*PERSPECTIVES*

**[Adapting environmental surveillance for polio to the need to track antimicrobial resistance](#)**

— Christine Årdal, David McAdams, Astrid Louise Wester & Sigrun Møgedal

<http://dx.doi.org/10.2471/BLT.20.258905>

**Child Care, Health and Development**

Volume 47, Issue 2 Pages: 143-296 March 2021

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

**Clinical Pharmacology & Therapeutics**

Volume 109, Issue 3 Pages: 547-781 March 2021

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[New issue; No digest content identified]

**Clinical Therapeutics**

January 2021 Volume 43 Issue 1 p1-210, e1-e32

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

**Clinical Trials**

Volume 18 Issue 1, February 2021

<https://journals.sagepub.com/toc/ctja/18/1>

[Reviewed earlier]

**Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 6 Mar 2021]

[No new digest content identified]

**Contemporary Clinical Trials**

Volume 100 January 2021

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/100/suppl/C>

[Reviewed earlier]

**The CRISPR Journal**

Volume 4, Issue 1 / February 2021

<https://www.liebertpub.com/toc/crispr/4/1>

[Reviewed earlier]



### **Current Genetic Medicine Reports**

Volume 8, issue 4, December 2020

<https://link.springer.com/journal/40142/volumes-and-issues/8-4>

[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

April 2021 - Volume 34 - Issue 2

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[New issue; No digest content identified]

### **Current Protocols in Human Genetics**

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

### **Developing World Bioethics**

Volume 21, Issue 1 Pages: i, 1-54 March 2021

<https://onlinelibrary.wiley.com/toc/14718847/current>

*ORIGINAL ARTICLES*

#### **[Lessons from the Ebola epidemics and their applications for COVID-19 pandemic response in sub-Saharan Africa](#)**

Muhammed O. Afolabi et al

Pages: 25-30

First Published: 12 July 2020

#### **[Allocation of scarce resources in Africa during COVID-19: Utility and justice for the bottom of the pyramid?](#)**

Keymanthri Moodley et al

Pages: 36-43

First Published: 26 August 2020

#### **[Considerations for stakeholder engagement and COVID-19 related clinical trials' conduct in sub-Saharan Africa](#)**

Morenike Oluwatoyin Folayan et al;

Pages: 44-50

First Published: 15 August 2020

#### ***ABSTRACT***

The aim of this study is to determine how stakeholder engagement can be adapted for the conduct of COVID-19-related clinical trials in sub-Saharan Africa. Nine essential stakeholder engagement practices were reviewed: formative research; stakeholder engagement plan; communications and issues management plan; protocol development; informed consent process; standard of prevention for vaccine research and standard of care for treatment research; policies on trial-related physical, psychological, financial, and/or social harms; trial accrual, follow-up, exit trial closure and results dissemination; and post-trial access to trial products or procedures. The norms, values, and practices of

collectivist societies in Sub-Saharan Africa and the low research literacy pose challenges to the conduct of clinical trials. Civil-society organizations, members of community advisory boards and ethics committees, young persons, COVID-19 survivors, researchers, government, and the private sector are assets for the implementation and translation of COVID-19 related clinical trials. Adapting ethics guidelines to the socio-cultural context of the region can facilitate achieving the aim of stakeholder engagement.

### **Development in Practice**

Volume 30, Issue 8, 2020

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 14 - Issue 5 - October 2020

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

### **Disasters**

Volume 45, Issue 1 Pages: 1-252 January 2021

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

### **EMBO Reports**

Volume 22 Issue 2 3 February 2021

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 27, Number 3—March 2021

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

### **Epidemics**

Volume 34 March 2021

<https://www.sciencedirect.com/journal/epidemics/vol/34/suppl/C>

*Research article Open access*

[\*\*Optimised prophylactic vaccination in metapopulations\*\*](#)

Mingmei Teo, Nigel Bean, Joshua V. Ross

Article 100420

*Highlights*

:: A flexible SIR stochastic metapopulation model is studied.

:: Insights to when it is best to allocate vaccines (pre-versus post-outbreak) and to whom they should be allocated are provided.

:: In practice it is generally optimal to distribute all vaccines prophylactically, rather than withholding vaccines.

:: An approximately optimal vaccination scheme is introduced and is shown to be consistently at least as good as three strategies reported in the literature.

#### *Abstract*

A highly effective method for controlling the spread of an infectious disease is vaccination. However, there are many situations where vaccines are in limited supply. The ability to determine, under this constraint, a vaccination strategy which minimises the number of people that become infected over the course of a potential epidemic is essential. Two questions naturally arise: when is it best to allocate vaccines, and to whom should they be allocated? We address these questions in the context of metapopulation models of disease spread. We discover that in practice it is generally optimal to distribute all vaccines prophylactically, rather than withholding until infection is introduced. For small metapopulations, we provide a method for determining the optimal prophylactic allocation. As the optimal strategy becomes computationally intensive to obtain when the population size increases, we detail an approximation method to determine an approximately optimal vaccination scheme. We find that our approximate strategy is consistently at least as good as three strategies reported in the literature across a wide range of parameter values.

### **Epidemiology and Infection**

Volume 149 - 2021

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

### **Ethics & Human Research**

Volume 43, Issue 1 January–February 2021

<https://onlinelibrary.wiley.com/toc/25782363/current>

***When disadvantaged by research • Privacy and medical records • Research misconduct***

[Reviewed earlier]

### **The European Journal of Public Health**

Volume 31, Issue 1, February 2021

<https://academic.oup.com/eurpub/issue/31/1>

[Reviewed earlier]

### **Expert Review of Vaccines**

Vol 19 (12) 2020

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

### **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 6 Mar 2021]

Software Tool Article metrics AWAITING PEER REVIEW

[Route Optimization Tool \(RoOT\) for distribution of vaccines and health products](#) [version 1; peer review: awaiting peer review]

Zelda B. Zabinsky, Mariam Zameer, Larissa P.G. Petroianu, Mamiza M. Muteia, Aida L. Coelho

Peer Reviewers Invited

Funder: Bill and Melinda Gates Foundation

PUBLISHED 01 Mar 2021

## Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 6 Mar 2021]

[No new digest content identified]

## Global Health Action

Volume 14, Issue 1 (2021)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

## Global Health: Science and Practice (GHSP)

Vol. 8, No. 4 December 23, 2020

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

## Global Public Health

Volume 16, Issue 3 (2021)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

## Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 6 Mar 2021]

[A survey of International Health Regulations National Focal Points experiences in carrying out their functions](#)

*The 2005 International Health Regulations (IHR (2005)) require States Parties to establish National Focal Points (NFPs) responsible for notifying the World Health Organization (WHO) of potential events that might constitute public health emergencies of international concern (PHEICs), such as outbreaks of novel infectious diseases. Given the critical role of NFPs in the global surveillance and response system supported by the IHR, we sought to assess their experiences in carrying out their functions.*

Authors: Corinne Packer, Sam F. Halabi, Helge Hollmeyer, Salima S. Mithani, Lindsay Wilson, Arne Ruckert, Ronald Labonté, David P. Fidler, Lawrence O. Gostin and Kumanan Wilson

Citation: Globalization and Health 2021 17:25

Content type: Research

Published on: 6 March 2021

### **COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa**

*The COVID-19 pandemic is a biosecurity threat, and many resource-rich countries are stockpiling and/or making plans to secure supplies of vaccine, therapeutics, and diagnostics for their citizens. We review the products that are being investigated for the prevention, diagnosis, and treatment of COVID-19; discuss the challenges that countries in sub-Saharan Africa may face with access to COVID-19 vaccine, therapeutics, and diagnostics due to the limited capacity to manufacture them in Africa; and make recommendations on actions to mitigate these challenges and ensure health security in sub-Saharan Africa during this unprecedented pandemic and future public-health crises.*

Authors: Bisi Bright, Chinedum Peace Babalola, Nadia Adjoa Sam-Agudu, Augustine Anayochukwu Onyeaghala, Adebola Olatunji, Ufuoma Aduh, Patrick O. Sobande, Trevor A. Crowell, Yenew Kebede Tebeje, Sunny Phillip, Nicaise Ndembi and Morenike Oluwatoyin Folayan

Citation: Globalization and Health 2021 17:24

Content type: Review

Published on: 3 March 2021

### **Health Affairs**

Vol. 40, No. 3 March 2021

<https://www.healthaffairs.org/toc/hlthaff/current>

### ***March 2021 | Nursing Homes, COVID-19 & More***

*Analysis COVID-19*

### **How New Models Of Vaccine Development For COVID-19 Have Helped Address An Epic Public Health Crisis**

David E. Bloom, Daniel Cadarette, Maddalena Ferranna, Randall N. Hyer, and Daniel L. Tortorice

Coronavirus disease 2019 (COVID-19) vaccine development and manufacturing have proceeded at a historically unprecedented pace. This speed may be accounted for by the unprecedented scale of resources being devoted to addressing COVID-19; an unusual ...

*Analysis COVID-19*

### **Reflections On Governance, Communication, And Equity: Challenges And Opportunities In COVID-19 Vaccination**

Daniel Salmon, Douglas J. Opel, Matthew Z. Dudley, Janesse Brewer, and Robert Breiman

### **Health and Human Rights**

Volume 22, Issue 2, December 2020

<https://www.hhrjournal.org/volume-22-issue-2-december-2020/>

### ***Special Section: Big Data, Technology, Artificial Intelligence and the Right to Health***

*Recent Viewpoints*

### **The Value of Human Rights for Vaccine Prioritization at the National Level**

Sharifah Sekalala, 8 February 2021

In this Viewpoint I argue that human rights have been largely left out of conversations about how to prioritise allocation within national vaccine programmes, but an intersectional human-rights approach is the fairest and most effective way to address COVID-19 vaccine prioritization.

### **Health Economics, Policy and Law**

Volume 16 - Special Issue 1 - January 2021

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

***SPECIAL ISSUE: The future of EU health law and policy***

[Reviewed earlier]

### **Health Policy and Planning**

Volume 36, Issue 1, February 2021

<https://academic.oup.com/heapol/issue/36/1>

*Original Articles*

**[Competing interests, clashing ideas and institutionalizing influence: insights into the political economy of malaria control from seven African countries](#)**

Justin Parkhurst, Ludovica Ghilardi, Jayne Webster, Robert W Snow, Caroline A Lynch

Health Policy and Planning, Volume 36, Issue 1, February 2021, Pages 35–44,

<https://doi.org/10.1093/heapol/czaa166>

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 6 Mar 2021]

[No new digest content identified]

### **Human Gene Therapy**

Volume 32, Issue 3-4 / February 2021

<https://www.liebertpub.com/toc/hum/32/3-4>

***Special Issue on Oncolytic Viruses/Cancer Immunotherapy***

[New issue; No digest content identified]

### **Humanitarian Exchange Magazine**

Number 78, October 2020

<https://odihpn.org/magazine/inclusion-of-persons-with-disabilities-in-humanitarian-action-what-now/>

**[Disability inclusion in humanitarian action](#)**

*by HPN October 2020*

The theme of this edition of Humanitarian Exchange, co-edited with Sherin Alsheikh Ahmed from Islamic Relief Worldwide, is disability inclusion in humanitarian action. Persons with disabilities are not only disproportionately impacted by conflicts, disasters and other emergencies, but also face barriers to accessing humanitarian assistance. At the same time, global commitments and standards and the IASC Guidelines on the inclusion of persons with disabilities in humanitarian action all emphasise how persons with disabilities are also active agents of change. Disability and age-focused organisations have led on testing and demonstrating how inclusion can be done better. Yet despite this progress, challenges to effective inclusion remain.

As Kirstin Lange notes in the lead article, chief among these challenges is humanitarian agencies' lack of engagement with organisations of persons with disabilities. Simone Bula, Elizabeth Morgan and

Teresa Thomson look at disability inclusion in humanitarian response in the Pacific, and Kathy Al Jubeh and Alradi Abdalla argue for a 'participation revolution', building on learning from the gender movement. Tchaurea Fleury and Sulayman AbdulMumuni Ujah outline how the Bridge Article 11 training initiative is encouraging constructive exchange between humanitarian and disability actors. The lack of good, disaggregated data is highlighted by Sarah Collinson; Frances Hill, Jim Cranshaw and Carys Hughes emphasise the need for training resources in local languages and accessible formats; and Sophie Van Eetvelt and colleagues report on a review of the evidence on inclusion of people with disabilities and older people.

Rebecca Molyneux and co-authors analyse the findings of a review of a DFID programme in north-east Nigeria, while Carolin Funke highlights the importance of strategic partnerships between disability-focused organisations, drawing on her research in Cox's Bazar. Sherin Alsheikh Ahmed describes Islamic Relief Worldwide's approach to mainstreaming protection and inclusion, while Pauline Thivillier and Valentina Shafina outline IRC's Client Responsive Programming. The edition ends with reflections by Mirela Turcanu and Yves Ngunzi Kahashi on CAFOD's SADI approach.

### **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 17, Issue 1, 2021

<https://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

### **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/content>

[Accessed 6 Mar 2021]

[No new digest content identified]

### **Infectious Diseases of Poverty**

<http://www.idpjournals.com/content>

[Accessed 6 Mar 2021]

[No new digest content identified]

### **International Journal of Community Medicine and Public Health**

Vol 8, No 3 (2021) March 2021

<https://www.ijcmph.com/index.php/ijcmph/issue/view/74>

*Table of Contents*

#### **[Knowledge, attitude and practice towards COVID-19 vaccination acceptance in West India](#)**

*This is a cross-sectional study done in an urban slum in Mumbai, India. The main outcome variable was the responses related to COVID-19 vaccine acceptance among the study participants.*

Shibal Bhartiya, Nishant Kumar, Tarundeep Singh, Sathiabalan Murugan, Saranya Rajavel, Meenakshi Wadhvani

#### **[A study on predictors of complete immunization in children aged 12-23 months in slums of Kanpur Nagar, India](#)**

*Educational status of the parents particularly mothers and the economic status of the family have great bearing on the immunization coverage of under 5 children. So female empowerment measures may prove helpful in improvement of the immunization status.*

Ruchi Chaturvedi, R. P. Sharma, D. S. Martolia, Tanu Midha

### **Attitude towards childhood vaccination among parents in a rural area of Trivandrum district**

*A cross-sectional study was carried out among parents of children below the age of 15 years, who are residents of a rural area in Thiruvananthapuram district. Data was collected using the parents' attitude about childhood vaccination (PACV) survey, with the consent of the participants. The collected data entered into MS Excel and analysis was carried out using SPSS 20.*

Nithya Girija, Deena Divakaran Sreelatha, Benny Purandaran Vasanthamani, Anil Bindhu Sukumaran, Regi Jose, Manju Leelavathy, Divija ., Ramiz Raja

### **International Journal of Epidemiology**

Volume 50, Issue 1, February 2021

<https://academic.oup.com/ije/issue>

[New issue; No digest content identified]

### **International Journal of Human Rights in Healthcare**

Volume 14 Issue 1 2021

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/1>

*Table of Contents*

[Reviewed earlier]

### **International Journal of Infectious Diseases**

February 2021 Volume 103 p1-654

<https://www.ijidonline.com/current>

[Reviewed earlier]

### **JAMA**

March 2, 2021, Vol 325, No. 9, Pages 805-898

<https://jamanetwork.com/journals/jama/currentissue>

*Viewpoint*

### **SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants**

John P. Moore, PhD; Paul A. Offit, MD

*free access has active quiz has multimedia has audio*

JAMA. 2021;325(9):821-822. doi:10.1001/jama.2021.1114

This Viewpoint reviews circulating SARS-CoV-2 genetic variants and mechanisms of immunity by which they might escape coronavirus vaccine-induced protection and proposes 6 measures to address them, including enhanced variant isolation and testing procedures and continued adherence to mask-wearing and other established public health measures.

[Audio Clinical Review:](#) Understanding SARS-CoV-2 Genetic Variants



[Conversations with Dr Bauchner:](#) Coronavirus Vaccine Update with Paul Offit and Robert Wachter

[Conversations with Dr Bauchner:](#) Coronavirus Update With Peter Piot, MD, PhD

[Conversations with Dr Bauchner:](#) Coronavirus Vaccine Update With Paul Offit – February 11, 2021

[Conversations with Dr Bauchner:](#) Coronavirus Vaccine Update From the CDC With Nancy E. Messonnier, MD

### **Funding of Pharmaceutical Innovation During and After the COVID-19 Pandemic**

James C. Robinson, PhD, MPH

free access has active quiz has audio

JAMA. 2021;325(9):825-826. doi:10.1001/jama.2020.25384

This Viewpoint considers whether the shift away from private investment toward government funding of drug and vaccine development and commercialization during the coronavirus disease 2019 (COVID-19) pandemic is sustainable, arguing that the same or greater level of public investment will be necessary if drug prices are to remain affordable and if the US wants to maintain its global leadership position.

[Conversations with Dr Bauchner:](#) Funding of Pharmaceutical Innovation During and After the COVID-19 Pandemic

#### *Editorial*

### **Vaccine Distribution—Equity Left Behind?**

Muriel Jean-Jacques, MD, MAPP; Howard Bauchner, MD

*free access has multimedia has audio*

JAMA. 2021;325(9):829-830. doi:10.1001/jama.2021.1205

The health disparities laid bare by the COVID-19 pandemic have not been surprising in their direction. Likewise, the inequities that are likely to manifest when a limited supply of vaccine is rolled out to a large number of eligible individuals are predictable. As local communities roll out vaccine distribution to those aged 65 and older it is important to consider potential challenges and to proactively plan for ways to mitigate likely disparities.

[1] Prioritize vaccine distribution to zip codes that have been most severely affected by COVID-19 and that have high indexes of economic hardship.

[2] Partner with local health care institutions, community organizations, and other trusted sources to promote vaccine awareness and uptake within local communities, with particular attention to institutions and organizations that serve communities who have borne the brunt of COVID-19 exposure, illness, and death.

[3] Prioritize vaccine distribution to those who face mobility or other transportation barriers to receipt of the vaccine (eg, vans to deliver vaccine to homebound older persons, vaccination sites that are near public transportation, and hours of operation that are accessible to those who work or who rely on those who work during standard business hours).

[4] Simplify registration procedures. Ensure registration options that do not require the internet or digital platforms (such as phone or in-person registration). Ensure registration is accessible to those with limited English proficiency or limited literacy. Registration should not require nonessential documentation, such as proof of citizenship, that is likely to deter individuals from immigrant communities from seeking vaccination. Offer vaccination options that do not require preregistration (eg, at local community centers, schools, houses of worship, or other highly frequented and trusted sites in the community)...

[Conversations with Dr Bauchner:](#) Who Gets Coronavirus Vaccine First?

[Conversations with Dr Bauchner:](#) Prioritizing Racial and Ethnic Minority Populations for Coronavirus Vaccination

[Conversations with Dr Bauchner:](#) Coronavirus Vaccine Update From the CDC With Nancy E. Messonnier, MD

#### *JAMA Live Highlights*

#### **[Experts Discuss COVID-19—Vaccine Doses, Virus Variants, and More](#)**

*free access has multimedia has audio*

JAMA. 2021;325(9):812-813. doi:10.1001/jama.2021.1101

JAMA Live Highlights features comments from livestream interviews by JAMA Network Editor in Chief Howard Bauchner, MD. His discussions with experts in clinical care, public health, and health policy focus on critical issues related to the [coronavirus disease 2019](#) (COVID-19) pandemic. Comments have been edited for clarity.

#### **JAMA Network**

#### **[COVID-19 Update March 6, 2021](#)**

*These articles on COVID-19 were published across the JAMA Network in the last week.*

#### **JAMA Pediatrics**

March 2021, Vol 175, No. 3, Pages 225-332

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

*Research Letter*

#### **[Number of Childhood and Adolescent Vaccinations Administered Before and After the COVID-19 Outbreak in Colorado](#)**

Sean T. O'Leary, MD, MPH; Lynnsay Trefren, MSN, RN; Heather Roth, MA; et al.

free access has active quiz

JAMA Pediatr. 2021;175(3):305-307. doi:10.1001/jamapediatrics.2020.4733

This study assesses the association of social distancing due to coronavirus disease 2019 (COVID-19) with immunizations administered by age category (0-2 years, 3-9 years, and 10-17 years) in Colorado.

#### **JBIS Evidence Synthesis**

February 2021 - Volume 19 - Issue 2

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

#### **Journal of Adolescent Health**

March 2021 Volume 68 Issue 3 p429-636

<https://www.jahonline.org/current>

[Reviewed earlier]

#### **Journal of Artificial Intelligence Research**

Vol. 70 (2021)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

**Journal of Community Health**

Volume 46, issue 2, April 2021

<https://link.springer.com/journal/10900/volumes-and-issues/46-2>

*Original Paper*

**COVID-19 Vaccination Hesitancy in the United States: A Rapid National Assessment**

Authors (first, second and last of 6) Jagdish Khubchandani, Sushil Sharma, Fern J. Webb

Published: 03 January 2021

Pages: 270 – 277

**Increasing HPV Vaccination Support Through a Pilot Film-Based Community Engagement**

Authors (first, second and last of 7) Shamly Austin, Katharine Wooten, Haiyan Qu

Content type: Original Paper

Published: 14 September 2020

Pages: 343 – 348

**Knowledge, Beliefs, and Practices Among U. S. College Students Concerning Papillomavirus Vaccination**

Authors - Bulaporn Natipagon-Shah, Eunice Lee, Shin-Young Lee

Content type: Original Paper

Published: 16 September 2020

Pages: 380 – 388

**Identification of the Knowledge Level of Students Receiving Health Education About the Human Papilloma Virus, Screening Tests, and Human Papilloma Virus Vaccination**

Authors - Gulpinar Aslan, Ayse Berivan Bakan, Content type: Original Paper

Published: 18 July 2020

Pages: 428 - 433

**Journal of Development Economics**

Volume 149 March 2021

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/149/suppl/C>

[Reviewed earlier]

**Journal of Empirical Research on Human Research Ethics**

Volume 15 Issue 5, December 2020

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

**Journal of Epidemiology & Community Health**

March 2021 - Volume 75 - 3

<https://jech.bmj.com/content/75/3>

[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 14, Issue 1 Pages: 1-81 February 2021

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

**Journal of Global Ethics**

Volume 16, Issue 2, 2020

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 32, Number 1, February 2021

<https://muse.jhu.edu/issue/43951>

*Table of Contents*

**[Institutional Distrust among African Americans and Building Trustworthiness in the COVID-19 Response: Implications for Ethical Public Health Practice](#)**

[Alicia L. Best](#), [Faith E. Fletcher](#), [Mika Kadono](#), [Rueben C. Warren](#)

pp. 90-98

**Journal of Immigrant and Minority Health**

Volume 23, issue 2, April 2021

<https://link.springer.com/journal/10903/volumes-and-issues/23-2>

[New issue; No digest content identified]

**Journal of Immigrant & Refugee Studies**

Volume 19, 2021\_ Issue 1

<https://www.tandfonline.com/toc/wimm20/current>

***Current Conflicts over Migration, Belonging and Membership: Classificatory Struggles Revisited***

[Reviewed earlier]

**Journal of Infectious Diseases**

Volume 223, Issue 3, 1 February 2021

<https://academic.oup.com/jid/issue/223/3>

[Reviewed earlier]

**Journal of Medical Ethics**

March 2021 - Volume 47 - 3

<http://jme.bmj.com/content/current>

*COVID-19 Current Controversies*

**Ethical allocation of future COVID-19 vaccines** (17 December, 2020) Free  
Rohit Gupta, Stephanie R Morain

**Global equitable access to vaccines, medicines and diagnostics for COVID-19: The role of patents as private governance** (30 November, 2020) Free  
Aisling McMahon

**Journal of Patient-Centered Research and Reviews**  
Volume 8, Issue 1 (2021)  
<https://digitalrepository.aurorahealthcare.org/jpcrr/>  
[Reviewed earlier]

**Journal of Pediatrics**  
March 2021 Volume 230 p1-282  
<http://www.jpeds.com/current>  
[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**  
<https://joppp.biomedcentral.com/>  
[Accessed 6 Mar 2021]  
[Reviewed earlier]

**Journal of Public Health Management & Practice**  
March/April 2021 - Volume 27 - Issue 2  
<https://journals.lww.com/jphmp/pages/currenttoc.aspx>  
[Reviewed earlier]

**Journal of Public Health Policy**  
Volume 41, issue 4, December 2020  
<https://link.springer.com/journal/41271/volumes-and-issues/41-4>  
[Reviewed earlier]

**Journal of Refugee & Global Health**  
Volume 4, Issue 1 (2021)  
<https://ir.library.louisville.edu/rgh/>  
[Reviewed earlier]

**Journal of the Royal Society – Interface**  
March 2021 Volume 18 Issue 176  
<https://royalsocietypublishing.org/toc/rsif/current>  
[New issue; No digest content identified]

### **Journal of Travel Medicine**

Volume 28, Issue 2, March 2021

[Reviewed earlier]

### **Journal of Virology**

February 2021; Volume 95, Issue 4

<http://jvi.asm.org/content/current>

[Reviewed earlier]

### **The Lancet**

Mar 06, 2021 Volume 397 Number 10277 p853-940

<https://www.thelancet.com/journals/lancet/issue/current>

*Editorial*

#### **Do we care about who cares?**

The Lancet

... As countries look to post-COVID-19 recovery, there is an urgent need for institutions and governments to redesign economies more equitably. They should be based on feminist, intersectional, and anti-racist principles that generate understanding of the inextricable link between, and need for social systems of, child care, value, and pay for domestic labour. Several pandemic recovery plans that espouse those principles have emerged. Recovery from the pandemic also calls us to think about the importance of investing in health and social care more generally, which will have the effect of freeing up the time of women who are the main producers of the unpaid care and unpaid caregiving by alleviating the burden of non-communicable disease and other long-term conditions and disabilities. COVID-19 has harmed the health and economic security of women worldwide. But the pandemic has also made the invisible contribution of women to health care much more apparent and provided important momentum to advocate for its measurement, recognition, and fair compensation with no disparities due to sex. This opportunity must be seized.

*Comment*

#### **Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster**

Ivan F N Hung, Gregory A Poland

... Important study limitations include the fact that these studies were not prospectively designed to establish whether vaccine efficacy would differ by dose interval; therefore, these post-hoc exploratory findings could be biased. Other limitations are that participants were not randomised to dosing interval, only one of the four trials was double-blind, and the single-dose recipients were self-selected. Furthermore, baseline characteristics between the single-dose and two-dose cohorts were substantially different, with an older median age, higher proportion of men and non-white participants, and a smaller proportion of health or social care workers in the two-dose cohort than in the single-dose cohort. Also, worth considering is whether these results would hold up with widespread circulation of more transmissible and lethal viral variants.

Overall, the value of this study is in providing evidence that a single dose of the ChAdOx1 nCoV-19 vaccine is highly efficacious in the 90 days after vaccination, that a longer prime-boost interval results in higher vaccine efficacy, and that protection against symptomatic COVID-19 is maintained despite a longer dosing interval. It offers much-needed evidence for the UK policy of extending the dosing

interval to 12 weeks and for rapid mass-immunisation campaigns worldwide. Further studies are warranted to assess whether a longer-interval strategy would also offer higher vaccine efficacy against the new variants<sup>8</sup> and could be applicable to other types of COVID-19 vaccines. <sup>9, 10, 11</sup>

#### *Articles*

#### **Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials**

Merryn Voysey, et al. on behalf of the Oxford COVID Vaccine Trial Group  
Open Access

The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4–12 weeks. The planned roll-out in the UK will involve vaccinating people in high-risk categories with their first dose immediately, and delivering the second dose 12 weeks later. Here, we provide both a further prespecified pooled analysis of trials of ChAdOx1 nCoV-19 and exploratory analyses of the impact on immunogenicity and efficacy of extending the interval between priming and booster doses. In addition, we show the immunogenicity and protection afforded by the first dose, before a booster dose has been offered.

#### *Review*

#### **Improving lung health in low-income and middle-income countries: from challenges to solutions**

Jamilah Meghji, et al.

#### *Summary*

Low-income and middle-income countries (LMICs) bear a disproportionately high burden of the global morbidity and mortality caused by chronic respiratory diseases (CRDs), including asthma, chronic obstructive pulmonary disease, bronchiectasis, and post-tuberculosis lung disease. CRDs are strongly associated with poverty, infectious diseases, and other non-communicable diseases (NCDs), and contribute to complex multi-morbidity, with major consequences for the lives and livelihoods of those affected. The relevance of CRDs to health and socioeconomic wellbeing is expected to increase in the decades ahead, as life expectancies rise and the competing risks of early childhood mortality and infectious diseases plateau. As such, the World Health Organization has identified the prevention and control of NCDs as an urgent development issue and essential to the achievement of the Sustainable Development Goals by 2030. In this Review, we focus on CRDs in LMICs. We discuss the early life origins of CRDs; challenges in their prevention, diagnosis, and management in LMICs; and pathways to solutions to achieve true universal health coverage.

#### **The Lancet Child & Adolescent Health**

Mar 2021 Volume 5 Number 3 p155-232, e6-e8  
<https://www.thelancet.com/journals/lanchi/issue/current>  
[Reviewed earlier]

#### **Lancet Digital Health**

Mar 2021 Volume 3 Number 3 e135-e203  
<https://www.thelancet.com/journals/landig/issue/current>  
[Reviewed earlier]

**Lancet Global Health**

Mar 2021 Volume 9 Number 3 e218-e371

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

**Lancet Infectious Diseases**

Mar 2021 Volume 21 Number 3 p297-438, e36-e63

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

**Lancet Public Health**

Mar 2021 Volume 6 Number 3 e136-e191

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

**Lancet Respiratory Medicine**

Mar 2021 Volume 9 Number 3 p217-318, e22-e29

<https://www.thelancet.com/journals/lanres/issue/current>

*Comment*

[\*\*An issue of trust—vaccinating Black patients against COVID-19\*\*](#)

Dale O Okorodudu, Daniel E Okorodudu

**Maternal and Child Health Journal**

Volume 25, issue 2, February 2021

<https://link.springer.com/journal/10995/volumes-and-issues/25-2>

[Reviewed earlier]

**Medical Decision Making (MDM)**

Volume 41 Issue 2, February 2021

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

**The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 98, Issue 4 Pages: 1021-1341, E1-E12 December 2020

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

**Nature**



Volume 591 Issue 7848, 4 March 2021

*Editorial* | 03 March 2021

**COVID is amplifying the inadequacy of research-evaluation processes**

Systems for assessing scientists' work must properly account for a lost year of research – especially for female researchers.

*Article* | 11 December 2020

**Genetic mechanisms of critical illness in COVID-19**

A genome-wide association study of critically ill patients with COVID-19 identifies genetic signals that relate to important host antiviral defence mechanisms and mediators of inflammatory organ damage that may be targeted by repurposing drug treatments.

Erola Pairo-Castineira, Sara Clohisey & J. Kenneth Baillie

**Nature Biotechnology**

Volume 39 Issue 2, February 2021

<https://www.nature.com/nbt/volumes/39/issues/2>

[Reviewed earlier]

**Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 6 Mar 2021)

[No new digest content identified]

**Nature Genetics**

Volume 53 Issue 2, February 2021

<https://www.nature.com/ng/volumes/53/issues/2>

[Reviewed earlier]

**Nature Human Behaviour**

Volume 5 Issue 2, February 2021

<https://www.nature.com/nathumbehav/volumes/5/issues/2>

[Reviewed earlier]

**Nature Medicine**

Volume 27 Issue 2, February 2021

<https://www.nature.com/nm/volumes/27/issues/2>

[Reviewed earlier]

**Nature Reviews Genetics**

Volume 22 Issue 3, March 2021

<https://www.nature.com/nrg/volumes/22/issues/3>

[Reviewed earlier]

## **Nature Reviews Immunology**

Volume 21 Issue 3, March 2021

<https://www.nature.com/nri/volumes/21/issues/3>

*Comment* | 05 January 2021

### **Endemic SARS-CoV-2 will maintain post-pandemic immunity**

Here, Veldhoen and Simas discuss why immunity to SARS-CoV-2 in populations may ultimately be driven by the endemic presence of the virus and not rely on continued mass vaccination programmes.  
Marc Veldhoen & J. Pedro Simas

## **Nature Reviews Drug Discovery**

Volume 20 Issue 3, March 2021

<https://www.nature.com/nrd/volumes/20/issues/3>

*Comment* | 28 May 2020

### **Supporting a data-driven approach to regulatory intelligence**

Drug developers are increasingly applying data-driven analysis of the actions of regulatory agencies to gain insights into their expectations and applications of regulatory policy, but such strategies can be limited by the availability and quality of regulatory datasets. Here, we discuss how establishing a single, robust, accessible database of FDA regulatory actions could help address this limitation.  
Andrew S. Robertson, Alexis Reisin Miller & Felipe Dolz

## **New England Journal of Medicine**

March 4, 2021 Vol. 384 No. 9

<http://www.nejm.org/toc/nejm/medical-journal>

*Editorials*

**Audio Interview: A New SARS-CoV-2 Vaccine and a New Look at Treatment** [E.J. Rubin, L.R. Baden, and S. Morrissey](#)

*Clinical Decisions*

**Delayed Second Dose versus Standard Regimen for Covid-19 Vaccination** [S.R. Kadire, R.M. Wachter, and N. Lurie](#)

## **Pediatrics**

Vol. 147, Issue 3 1 Mar 2021

<https://pediatrics.aappublications.org/>

*Research Briefs*

### **HPV Vaccine Recommendations and Parental Intent**

Kalyani Sonawane, Yenan Zhu, Yueh-Yun Lin, Haluk Damgacioglu, Ying Lin, Jane R. Montealegre, Ashish A. Deshmukh  
Pediatrics, Mar 2021, 147 (3) e2020026286

*Review Articles*

**Improving Influenza Vaccination in Children With Comorbidities: A Systematic Review**

Daniel A. Norman, Rosanne Barnes, Rebecca Pavlos, Mejbah Bhuiyan, Kefyalew Addis Alene, Margie Danchin, Holly Seale, Hannah C. Moore, Christopher C. Blyth  
Pediatrics, Mar 2021, 147 (3) e20201433

### **PharmacoEconomics**

Volume 39, issue 3, March 2021

<https://link.springer.com/journal/40273/volumes-and-issues/39-3>

[Reviewed earlier]

### **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 6 Mar 2021)

[No new digest content identified]

### **PLoS Medicine**

<http://www.plosmedicine.org/>

(Accessed 6 Mar 2021)

[No new digest content identified]

### **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 6 Mar 2021)

[No new digest content identified]

### **PLoS One**

<http://www.plosone.org/>

[Accessed 6 Mar 2021]

[Allocating epidemic response teams and vaccine deliveries by drone in generic network structures, according to expected prevented exposures](#)

Dean Matter, Linke Potgieter

Research Article | published 05 Mar 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0248053>

[Control strategies for COVID-19 epidemic with vaccination, shield immunity and quarantine: A metric temporal logic approach](#)

Zhe Xu, Bo Wu, Ufuk Topcu

Research Article | published 05 Mar 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0247660>

[The exposure risk to COVID-19 in most affected countries: A vulnerability assessment model](#)

Adriana Nascimento Santos Cartaxo, Francisco Iran Cartaxo Barbosa, Paulo Henrique de Souza Bermejo, Marina Figueiredo Moreira, David Nadler Prata

Research Article | published 04 Mar 2021 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0248075>

**Oral health care professionals recommending and administering the HPV vaccine: Understanding the strengths and assessing the barriers**

Denise Guadiana, Nolan M. Kavanagh, Cristiane H. Squarize  
Research Article | published 04 Mar 2021 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0248047>

**The anti-vaccination infodemic on social media: A behavioral analysis**

Federico Germani, Nikola Biller-Andorno  
Research Article | published 03 Mar 2021 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0247642>

**PLoS Pathogens**

<http://journals.plos.org/plospathogens/>  
[Accessed 6 Mar 2021]  
[No new digest content identified]

**PNAS - Proceedings of the National Academy of Sciences of the United States of America**

March 02, 2021; vol. 118 no. 9  
<https://www.pnas.org/content/118/9>  
[New issue: No digest content identified]

**Prehospital & Disaster Medicine**

Volume 36 - Issue 2 - April 2021  
<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>  
[New issue: No digest content identified]

**Preventive Medicine**

Volume 143 February 2021  
<https://www.sciencedirect.com/journal/preventive-medicine/vol/143/suppl/C>  
[Reviewed earlier]

**Proceedings of the Royal Society B**

10 March 2021 Volume 288 Issue 1946  
<https://royalsocietypublishing.org/toc/rspb/current>  
[New issue: No digest content identified]

**Public Health**

Volume 191 Pages 1-90 (February 2021)

<https://www.sciencedirect.com/journal/public-health/vol/191/suppl/C>  
[New issue: No digest content identified]

### **Public Health Ethics**

Volume 13, Issue 3, November 2020  
<http://phe.oxfordjournals.org/content/current>  
[Reviewed earlier]

### **Public Health Reports**

Volume 136 Issue 2, March/April 2021  
<https://journals.sagepub.com/toc/phrg/136/2>  
[Reviewed earlier]

### **Qualitative Health Research**

Volume 31 Issue 4, March 2021  
<http://qhr.sagepub.com/content/current>  
[Reviewed earlier]

### **Research Ethics**

Volume 17 Issue 1, January 2021  
<http://journals.sagepub.com/toc/reab/current>  
[Reviewed earlier]

### **Reproductive Health**

<http://www.reproductive-health-journal.com/content>  
[Accessed 6 Mar 2021]  
[No new digest content identified]

### **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>  
*Selected Articles*  
[No new digest content identified]

### **Risk Analysis**

Volume 41, Issue 3 Pages: 407-557 March 2021  
<https://onlinelibrary.wiley.com/toc/15396924/current>  
***Special Issue:40 Years of Social Sciences in Risk Research Reconsidered***  
*Original Research Articles*  
**[Trust and Risk Perception: A Critical Review of the Literature](#)**  
Michael Siegrist

Pages: 480-490

First Published: 02 May 2019

#### *Abstract*

Many studies in the field of risk perception and acceptance of hazards include trust as an explanatory variable. Despite this, the importance of trust has often been questioned. The relevant issue is not only whether trust is crucial but also the form of trust that people rely on in a given situation. In this review, I discuss various trust models and the relationship between trust and affect heuristics. I conclude that the importance of trust varies by hazard and respondent group. Most of the studies use surveys that provide limited information about causality. Future research should focus more on experiments that test whether trust is a consequence of people's attitudes or influences their attitudes toward a technology. Furthermore, there is a need for a better understanding about the factors that determine which heuristics people rely on when evaluating hazards.

#### **The Coming of Age of Risk Governance**

Andreas Klinke, Ortwin Renn

Pages: 544-557

First Published: 05 August 2019

#### **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 6 Mar 2021]

[No new digest content identified]

#### **Science**

05 March 2021 Vol 371, Issue 6533

<http://www.sciencemag.org/current.dtl>

#### *Editorial*

#### **Science's new frontier**

By Aaron F. Mertz, Abhilash Mishra

Science 05 Mar 2021 : 96

#### *Summary*

The year 2020 saw a reusable rocket launch two astronauts into space, multiple COVID-19 vaccines developed in record time, and a robot that could write a persuasive op-ed. In the United States, the year also saw public distrust of science contribute to the worst health crisis in modern history. This contrast highlights a sharp dichotomy in the role of science in American public life: breathtaking discovery and innovation alongside growing distrust of scientific evidence and recommendations. How can the country reconcile this dissociation?

#### *Policy Forum*

#### **Human embryo research beyond the primitive streak**

By Insoo Hyun, Annelien L. Bredenoord, James Briscoe, Sigal Klipstein, Tao Tan

Science 05 Mar 2021 : 998-1000 Restricted Access

*It is time to revisit the "14-day limit"*

#### *Summary*

Since the first successful birth resulting from in vitro fertilization (IVF) in the late 1970s, human embryo research has been subject to limits of time and developmental benchmarks. National guidelines, laws,

and international norms have prohibited scientists from culturing embryos for research beyond 14 consecutive days, or beyond the appearance of a structure called the “primitive streak,” which defines the beginning of the formation of the principal tissues of the body and the end of the period when an embryo can divide into identical twins (1). At the time this limit was put in place 40 years ago, there were no methods to culture embryos in a dish for anywhere close to 14 days. But research since 2016 (2, 3) shows that it is likely possible to culture human research embryos past the 2-week limit and suggests that doing so will yield scientific insights that could prove important for human health and fertility (4). We thus urge policy-makers and the International Society for Stem Cell Research (ISSCR), which will soon release updated guidelines for stem cell and embryo research, to consider a cautious, stepwise approach to scientific exploration beyond the 14-day limit.

*Review*

### **Infectious diseases and social distancing in nature**

By Sebastian Stockmaier, Nathalie Stroeymeyt, Eric C. Shattuck, Dana M. Hawley, Lauren Ancel Meyers, Daniel I. Bolnick

Science 05 Mar 2021

#### *Nature's "responsible" response to disease*

With the emergence of the COVID-19 pandemic, there have been global calls for the implementation of “social distancing” to control transmission. Throughout the world, some have resisted this requirement with the unfounded argument that it is unnecessary or ineffective. Social distancing, however, is a natural consequence of disease across animals, both human and nonhuman. Stockmaier et al. reviewed responses to disease across animal taxa and reveal how these responses naturally limit disease transmission. Understanding such natural responses and their impacts on pathogenic transmission provides epidemiological insight into our own responses to pandemic challenges.

#### *Abstract*

Spread of contagious pathogens critically depends on the number and types of contacts between infectious and susceptible hosts. Changes in social behavior by susceptible, exposed, or sick individuals thus have far-reaching downstream consequences for infectious disease spread. Although “social distancing” is now an all too familiar strategy for managing COVID-19, nonhuman animals also exhibit pathogen-induced changes in social interactions. Here, we synthesize the effects of infectious pathogens on social interactions in animals (including humans), review what is known about underlying mechanisms, and consider implications for evolution and epidemiology.

### **Science Translational Medicine**

03 March 2021 Vol 13, Issue 583

<https://stm.sciencemag.org/>

[New issue; No digest content identified]

### **Social Science & Medicine**

Volume 270 February 2021

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/270/suppl/C>

[Reviewed earlier]

### **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 6 Mar 2021]  
<https://stm.sciencemag.org/>  
[No new digest content identified]

### **Theoretical Medicine and Bioethics**

Volume 41, issue 5-6, December 2020

<https://link.springer.com/journal/11017/volumes-and-issues/41-5>

*Original Paper*

#### **[The concept of disease in the time of COVID-19](#)**

Authors - Maria Cristina Amoretti, Elisabetta Lalumera

Open Access

Published: 01 December 2020

Pages: 203 - 221

### **Travel Medicine and Infectious Diseases**

Volume 39 January–February 2021

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/39/suppl/C>

[Reviewed earlier]

### **Tropical Medicine & International Health**

Volume 26, Issue 3 Pages: i-iv, 257-384 March 2021

<https://onlinelibrary.wiley.com/toc/13653156/current>

[New issue: No digest content identified]

### **Vaccine**

Volume 39, Issue 11 Pages 1547-1666 (12 March 2021)

<https://www.sciencedirect.com/journal/vaccine/vol/39/issue/11>

*Editorial Full text access*

#### **[Improving COVID-19 vaccine acceptance: Including insights from human decision-making under conditions of uncertainty and human-centered design](#)**

Caroline M. Poland, Allison K.S. Matthews, Gregory A. Poland

Pages 1547-1550

*Review article Open access*

#### **[Situational assessment of adult vaccine preventable disease and the potential for immunization advocacy and policy in low- and middle-income countries](#)**

Molly Sauer, Prarthana Vasudevan, Ankita Meghani, Karuna Luthra, ... Lois Privor-Dumm

Pages 1556-1564

### **Vaccines — Open Access Journal**

<http://www.mdpi.com/journal/vaccines>

(Accessed 6 Mar 2021)

Open Access Article



### **Acceptability of a COVID-19 Vaccine among the Saudi Population**

by Eman Ibrahim Alfageeh et al.

Vaccines 2021, 9(3), 226; <https://doi.org/10.3390/vaccines9030226> - 05 Mar 2021

#### *Abstract*

To investigate the associated factors underlying vaccination intentions for Coronavirus Disease 2019 (COVID-19), an online cross-sectional survey was conducted among adults 18 years or over in the Kingdom of Saudi Arabia. Data were collected between 8 and 14 December 2020. A logistic regression [...] R

#### *Open Access Article*

### **Attitude and Behaviors towards SARS-CoV-2 Vaccination among Healthcare Workers: A Cross-Sectional Study from Poland**

by Bartosz Szmyd et al

Vaccines 2021, 9(3), 218; <https://doi.org/10.3390/vaccines9030218> - 04 Mar 2021

#### *Abstract*

Healthcare workers are particularly exposed to biological risk during their daily occupational activities. Nowadays, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become one of the most widespread infectious agents. In the current study, we performed a survey on the attitude and behavior [...]

#### *Open Access Article*

### **Acceptance of a COVID-19 Vaccine in Japan during the COVID-19 Pandemic**

by Masaki Machida et al.

Vaccines 2021, 9(3), 210; <https://doi.org/10.3390/vaccines9030210> - 03 Mar 2021

#### *Abstract*

Vaccination could be a key protective measure against coronavirus disease 2019 (COVID-19), and it is important to understand the acceptability of the COVID-19 vaccine among the general public. However, there is no study on the acceptance of a COVID-19 vaccine in Japan. Therefore, [...]

#### *Open Access Article*

### **COVID-19 Vaccine Acceptance among an Online Sample of Sexual and Gender Minority Men and Transgender Women**

by Daniel Teixeira da Silva et al

Vaccines 2021, 9(3), 204; <https://doi.org/10.3390/vaccines9030204> - 01 Mar 2021

#### *Abstract*

Sexual and gender minority (SGM) populations are particularly vulnerable to poor COVID-19 outcomes and are more likely to experience stigma and medical mistrust that may impact COVID-19 vaccine acceptance. This study examined the prevalence of COVID testing and diagnosis and assessed COVID-19 vaccine [...]

### **Value in Health**

March 2021 Volume 24 Issue 3 p313-462

<https://www.valueinhealthjournal.com/current>

[New issue; No digest content identified]

\*

\*

\*

\*

## **Media/Policy Watch**

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. *Media Watch* is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from *Journal Watch* above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

### **The Atlantic**

<http://www.theatlantic.com/magazine/>

*Accessed 6 Mar 2021*

*Ideas*

#### **America's Legalistic Culture Is About to Become a Problem**

*The vaccine rollout will create new clashes between conflicting rights.*

March 4, 2021

Jamal Greene, Professor at Columbia Law School

As vaccine production and distribution accelerate, a new set of challenges around what Americans can and should demand of one another is emerging. And we're not ready for them. The public has been told for the past year that we need to mask up, physically distance, and lock down for the greater good. Now that vaccines are here, does that same greater good mean that society can discriminate against the unvaccinated? Do Americans have a right not to get vaccinated? If so, how far does that right go?

### **BBC**

<http://www.bbc.co.uk/>

*Accessed 6 Mar 2021*

[No new, unique, relevant content]

### **The Economist**

<http://www.economist.com/>

*Accessed 6 Mar 2021*

*Bartleby*

#### **How companies should handle vaccines**

*Balancing the rights of stakeholders*

THE PANDEMIC is throwing up a new set of ethical issues for businesses. The premise of "stakeholder capitalism" is not just that firms should consider the interests of employees and customers, as well as shareholders. It is that, by doing so, everyone gains; shareholders will prosper if workers and customers are treated decently. But the pandemic may put different groups at odds. For example, customers may want companies to insist that all employees are vaccinated, while not wanting the same rule to apply to themselves.

Mar 6th 2021

## **Financial Times**

<https://www.ft.com/>

*Accessed 6 Mar 2021*

*Covid-19 vaccines*

### **EU turns to US in scramble for Oxford/AstraZeneca vaccine**

Move is part of bloc's effort to boost faltering immunisation programme

Sam Fleming and Michael Peel in Brussels, and Kiran Stacey in Washington

March 6

The EU will urge the US to permit the export of millions of doses of AstraZeneca's Covid-19 vaccine to Europe as Brussels scrambles to bridge supply shortfalls that have hobbled its inoculation drive.

The European Commission plans to raise the matter in forthcoming transatlantic discussions aimed at boosting collaboration on the fight against Covid-19, EU officials said.

The EU also wants Washington to ensure the free flow of shipments of crucial vaccine ingredients needed in European production, including for groundbreaking mRNA technology vaccines...

*Coronavirus:*

### **Germany urges EU coordination after Italy blocks vaccine shipment**

Germany has urged caution on vaccines, after France backed Italy's decision to block a shipment of jabs to Australia.

The German health minister on Friday said that such unilateral steps were unhelpful and could disrupt supply chains, adding that Europe should act in a more coordinated way when it comes to such export restrictions.

March 5, 2021

## **Forbes**

<http://www.forbes.com/>

*Accessed 6 Mar 2021*

Mar 6, 2021

### **Europe's Vaccine Struggle Will Change Its Politics**

France and much of Europe has fallen behind with vaccinating its citizens, this may lead to political stress down the line and raises questions as to what countries are ready for the post COVID world.

By Mike O'Sullivan Senior Contributor

Mar 5, 2021

### **How Pfizer's Head Of Vaccine Development Made Covid-19 Vaccine In Record Time And Led A Large Team**

Kathrin Jansen has made waves in healthcare having led the development of Gardasil, now the Covid-19 vaccine and others. She leads with strength, organization and often, creativity and gut instincts. During the pandemic she led hundreds of people on this mission to develop an effective vaccine.

By Monica Haider Contributor

Mar 5, 2021

### **Fauci Says Military Who Refuse Covid-19 Vaccine Are 'Part Of The Problem' After High Rate Of Service Members Refuse Jab**

Pentagon officials have said one in three military troops are refusing to take the optional Covid-19 shot.

By Robert Hart Forbes Staff

## **Foreign Affairs**

<http://www.foreignaffairs.com/>

*Accessed 6 Mar 2021*

[No new, unique, relevant content]

## **Foreign Policy**

<http://foreignpolicy.com/>

*Accessed 6 Mar 2021*

*Argument*

### **To Democratize Vaccine Access, Democratize Production**

U.S. and European COVID-19 shots aren't enough. It is time to tap into Africa, Asia, and Latin America's enormous production capacity.

By [Matthew M. Kavanagh](#), [Mara Pillinger](#), [Renu Singh](#), [Katherine Ginsbach](#)

## **The Guardian**

<http://www.guardiannews.com/>

*Accessed 6 Mar 2021*

[No new, unique, relevant content]

## **New Yorker**

<http://www.newyorker.com/>

*Accessed 6 Mar 2021*

*Annals of Populism*

### **The Vaccine Resisters**

Why do so many people say that they won't be immunized against COVID-19?

By Benjamin Wallace-Wells

March 5, 2021

## **New York Times**

<http://www.nytimes.com/>

*Accessed 6 Mar 2021*

*The Interpreter*

### **Vaccine Passports, Covid's Next Political Flash Point**

A world divided between the vaccinated and unvaccinated promises relief for economies and families, but the ethical and practical risks are high.

March 2, 2021

## **Washington Post**

<https://www.washingtonpost.com/>

*Accessed 6 Mar 2021*

### **Tibetan spiritual leader Dalai Lama gets vaccine shot**

Associated Press · Mar 6, 2021

### **After days of halting statements about vaccine morality, multiple Catholic leaders call the shots urgent, important**

Michelle Boorstein · Religion · Mar 5, 2021

**WHO head pushes for waiver of some intellectual property rights for coronavirus vaccines, in bid to broaden access**

Miriam Berger · World · Mar 5, 2021

**France backs Italy in vaccine ban as EU defends mechanism**

BRUSSELS — Europe's vaccine solidarity got a boost on Friday after France said it could emulate Italy's move to block coronavirus vaccine exports outside the European Union if that's what is needed to enforce the bloc's own contracts with drugs manufacturers.

Mar 5, 2021

\* \* \* \*

**Think Tanks et al**

**Brookings**

<http://www.brookings.edu/>

Accessed 6 Mar 2021

Coronavirus (COVID-19)

**One year in, COVID-19's uneven spread across the US continues**

William H. Frey

Friday, March 5, 2021

FixGov

**Getting the COVID-19 vaccine: Progress, and equity questions for the next phase**

Elaine Kamarck and William A. Galston

Thursday, March 4, 2021

Coronavirus (COVID-19)

**Examining and addressing COVID-19 racial disparities in Detroit**

Rashawn Ray, Jane Fran Morgan, Lydia Wileden, Samantha Elizondo, and Destiny Wiley-Yancy

Tuesday, March 2, 2021

**Center for Global Development** [to 6 Mar 2021]

<http://www.cgdev.org/page/press-center>

Publication

**Equity and Scale in Global Immunization: New Evidence from Nigeria on Cash Transfers for Vaccination**

Event

3/10/21

Even prior to COVID-19, full immunization for age was vastly unequal in large middle-income countries like Nigeria. As the COVID-19 crisis deepens, routine immunization has plummeted, and world leaders are seeking ways to regain ground and trust, even while considering how to roll out a COVID-19 vaccine.

**Global Trends in 2021: How COVID-19 Is Transforming International Development**

Publication

3/2/21

In this note, we explore some of the changes and trends in development agency strategic direction brought about by the pandemic, as well as fundamental challenges that bilateral development agencies will need to address in the years to come.

**Chatham House** [to 6 Mar 2021]

<https://www.chathamhouse.org/>

*Accessed 6 Mar 2021*

[No new digest content identified]

**CSIS**

<https://www.csis.org/>

*Accessed 6 Mar 2021*

*Upcoming Event*

**[A Conversation with Dr. Anthony Fauci and Professor Paul Kelly](#)**

March 9, 2021

*Transcript*

**[A Global Approach to COVID-19 Vaccination](#)**

March 4, 2021

**Kaiser Family Foundation**

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

*Accessed 6 Mar 2021*

March 4, 2021 *News Release*

**[THE CONVERSATION: Between Us, About Us, A New Campaign By Black Health Care Workers for Black People about the COVID-19 Vaccines](#)**

March 4, 2021 – THE CONVERSATION: Between Us, About Us. is a new campaign to provide Black communities with credible information about the COVID-19 vaccines co-developed by KFF (Kaiser Family Foundation) and the Black Coalition Against COVID. Black doctors, nurses and researchers dispel misinformation and provide accessible facts in 50...

March 3, 2021 *News Release*

**[KFF Tracking Poll: More Than a Third of Americans Say They've Struggled to Pay Living Expenses Since December; 6 in 10 Families Hit by COVID Have Lost A Job or Income](#)**

Majorities Favor Provisions to Expand Marketplace Tax Credits and Encourage States to Expand Medicaid As Congress considers an additional \$1.9 trillion COVID-19 relief plan, more than a third (37%) of Americans say that someone in their household has had trouble paying basic living expenses over the past three months, the...

March 1, 2021 *News Release*

**[Many Nonelderly People With Disabilities Face COVID-19 Risks Similar to Those of the Elderly in Nursing Homes, But Do Not Have Equal Footing When it Comes to Vaccine Priority](#)**

While the toll of COVID-19 on nursing home residents has been well documented, less noticed has been the experience of nonelderly people with disabilities who rely on long-term care services and supports outside of nursing homes. In many ways the two groups face similar health risks from the virus, but...

March 1, 2021 *News Release*

**Analysis: Spending on Health Care Would Drop by an Estimated \$352 Billion in 2021 if Private Insurance Used Medicare Rates to Reimburse Hospitals and Other Health Care Providers**

Total health care spending for people with private health insurance would be an estimated \$352 billion lower in 2021 if private insurers used Medicare rates to pay hospitals and other health care providers, rather than the substantially higher rates they currently pay, a new KFF analysis finds. That would represent...

**Urban Institute** [to 6 Mar 2021]

<https://www.urban.org/publications>

*Publications*

**Reforming Long-Term Care with Lessons from the COVID-19 Pandemic**

In October 2020, the Urban Institute hosted a roundtable of leading experts to discuss how the US cares for older adults in the wake of the COVID-19 pandemic. Participants highlighted key areas for reform and identified potential improvements. These included redesigning Medicaid; creating a strong foundation for home- and community-based services; integrating medical care and long-term services and

[Howard Gleckman](#), [Melissa M. Favreault](#)

March 2, 2021

Brief

**World Economic Forum** [to 6 Mar 2021]

<https://agenda.weforum.org/news/>

*Media*

[No new relevant content]

*	*	*	*
*	*	*	*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/3.0/>). Copyright is retained by CVEP.

*CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable*

*development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.*

*Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute , PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).*

*Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.*

*	*	*	*
*	*	*	*